Associations of depression and anxiety symptoms with cardiac function and cardiovascular disease in the general population A linkage between the HUNT population study, hospital data and cause-of death register by Gustad, Lise Tuset
Associations of depression 
and anxiety symptoms with 
cardiac function and cardiovas-
cular disease in the general 
population
A linkage between the HUNT population 
study, hospital data and cause-of death 
register
Thesis for the degree of Philosophiae Doctor
Trondheim, May 2015
Norwegian University of Science and Technology
Faculty of Medicine
Department of Neuroscience
Lise Tuset Gustad
NTNU
Norwegian University of Science and Technology
Thesis for the degree of Philosophiae Doctor
Faculty of Medicine
Department of Neuroscience
© Lise Tuset Gustad
ISBN 978-82-326-0856-0 (printed ver.)
ISBN 978-82-326-0857-7 (electronic ver.)
ISSN 1503-8181 
Doctoral theses at NTNU, 2015:100
Printed by NTNU Grafisk senter
 
 
Norsk Sammendrag (Norwegian Summary) 
Anslagvis rammes hvert år 10–30% av Norges og den vestlige verdens befolkning av en 
psykisk lidelse. I løpet av livet får mellom 30 og 50% en slik lidelse. De vanligste 
psykiske lidelsene er angst og depresjon, og disse tilstandene bidrar også til økt 
sykelighet og dødelighet ved flere somatiske sykdommer, inkludert hjerte-karsykdom 
(CVD). Hver tredje nordmann rammes av CVD i løpet av livet, og er i dag sammen med 
kreft vanligste årsak til død i Norge. Forskning antyder at angst- og depresjons-
symptomer også bidrar til selve utviklingen av CVD, blant annet gjennom ugunstig 
livsstil (som røyking, alkohol, inaktivitet, og inntak av fet mat) som igjen øker 
blodtrykk, BMI og kolestrolnivå. De tre siste faktorene er noen av de viktigste faktorene 
bak inflammasjon og arteriosklerotiske prosesser som bidrar til CVD. Tidligere 
forskning har ikke tatt tilstrekkelig høyde for disse mellomliggende faktorene, slik at de 
underliggende mekanismene mellom psykisk helse og CVD fortsatt er noe uavklart. 
Helseundersøkelsen i Nord-Trøndelag (HUNT) er en stor befolkningsundersøkelse som 
har registrert mange av disse forklaringsvariablene som mangler i tidligere studier. Alle 
nordtrøndere over 20 år har blitt invitert til disse undersøkelsene (HUNT1, 1984–86; 
HUNT2, 1995–97; HUNT3, 2007–09), hvor det er gjort klinisk undersøkelser, 
blodprøvetaking og utfylling av spørreskjema. I spørreskjemaene ble det spurt om siste 
ukes symptomer på angst (HADS-A) og depresjon (HADS-D).  
Sykehusene i Helse Nord-Trøndelag HF (HNT) i Levanger og Namsos har 
siden 1995 registrert opplysninger om diagnostikk, prøveresultater og behandling av 
alle pasienter med hjerteinfarkt (AMI) og hjertesvikt (HF). Det kardiologiske miljøet 
har kvalitetssikret denne informasjonen og validert diagnosene, og dermed sikret høy 
spesifisitet for diagnosene, før kobling med HUNT data.  
Artikkel I og II undersøkte den prospektive sammenhengen mellom 
selvrapporterte symptomer på depresjon, angst og blandet angst og depresjon (MSAD) 
hos personer uten hjertesykdom i HUNT2, og utvikling av førstegangs hjerteinfarkt 
(AMI, artikkel I) og hjertesvikt (HF, artikkel II) fram til 31.12.2008. Endepunktene ble 
registrert både i sykehusjournaler og i Dødsårsaksregisteret. Artikkel I viste 20–30% økt 
risiko for fremtidig førstegangs AMI forbundet med symptomer på angst, depresjon og 
MSAD i HUNT2. Artikkel II viste at symptomer på depresjon, men ikke angst eller 
MSAD, ga ca. 40% økt risiko for å få diagnosen HF i løpet av oppfølgingsperioden. 
I manuskript III studerte vi sammenhengen mellom angst- eller 
depresjonssymptomer og venstre hjertekammerfunksjon. Ett tilfeldig utvalg av friske 
HUNT3 deltagere uten hypertensjon, diabetes eller kjent klaffesykdom gjennomgikk 
ekkokardiografiundersøkelse. Vi fant ingen sammenheng mellom angst og 
depresjonssymptomer rapportert i HUNT3 og hjertefunksjon målt på samme tidspunkt. 
 
 
Men summen av depresjonssymptomer fra HUNT2 og HUNT3 var assosiert med 
svekkelse av den diastoliske hjertefunksjonen i HUNT3, ca. 1 % svekkelse for hvert 
poeng/enhets økning på HADS-D skalaen, både for kvinner og menn Vi fant ingen slike 
sammenhenger for angstsymptomer. 
Screening for angst- og depresjonssymptomer er en godt tolerert og 
ressursbesparende metode som kan brukes i de fleste kontekster. Våre resultater 
bekrefter at det er særlig viktig å vurdere depresjonssymptomene (alvorlighet og 
varighet) når det gjelder forebygging av CVD. 
Kandidat: Lise Tuset Gustad 
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1.0 Introduction 
Depression is often characterized by symptoms of sadness, loss of interest, concentration, 
pleasure or appetite, guilt, negative thoughts and tiredness, whilst anxiety is more typically 
characterized by tension and worrying, often followed by physiological changes such as 
increased blood pressure, heart rate and sweating (1). These symptoms often represent 
indicators for underlying stress, both from internal and external factors, and they are highly 
prevalent in the general population. World-wide, approximately 400 million people are 
affected by depressive disorders and 272 million people by anxiety disorders (2). Further, 
there has been an increasing awareness that anxiety and depression disorders, but also anxiety 
and depression symptoms, could be linked to a broad spectrum of physical illnesses (2), 
including cardiovascular disease (CVD) (3-8). 
CVD includes diseases of the heart and circulation (9). The focus in this thesis is on 
the influence of anxiety and depression symptoms on the development of acute myocardial 
infarction (AMI) and heart failure (HF) and on subclinical left ventricular (LV) dysfunction. 
Around 17.3 million people died from CVDs in 2008, representing 30% of all deaths in the 
world (10). WHO estimates that this number will increase to 23.3 million by 2030 (10). As 
CVD usually develops over decades and the progression rate is influenced by a variety of 
cardiovascular risk factors (11), it is crucial to identify modifiable risk factors early in this 
process. Today, the American Heart Association promotes a lifelong focus on seven health 
metrics; four health behaviours (healthy diet pattern, appropriate energy intake, physical 
activity and non-smoking) and three health factors (optimal blood lipids. blood pressure and 
glucose levels) in order to improve cardiovascular health (12).  
Psychosocial factors like anxiety and depression, representing modifiable risk 
factors, have in the last decade been identified to be independent and highly prevalent risk 
factors for CVD (3-5, 8, 11, 13, 14). However, the nature of these associations remains 
controversial. The aim of this thesis is to contribute to a better understanding of the 
association of depression and anxiety symptoms with future AMI (paper I), HF (paper II) and 
present subclinical LV dysfunction (study III), controlling for potential confounders, 
including comorbid physical illnesses in a large population-based cohort. 
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2. Background 
2.1 Cardiovascular Disease (CVD) 
The strong interest for epidemiological research on CVD and CVD risk factors awoke 
in the mid-20th century, probably because most regions in the world then experienced a 
sharp rise in CVD mortality (15). Figure 1 displays the trend of CVD mortality in 
Scandinavia between 1950 and 2000 as depicted by Mirzaei et al. 2009 (15)1.  
 
Figure 1: Age adjusted secular trend of CVD mortality in Scandinavia 1950-2000. 
As Figure 1 shows, there was a peak in CVD mortality in Norway around 1970. The 
improved prognosis in established CVD after 1985 is mostly explained by the 
development of surgical and medical treatment (16). In most high-income countries 
universal access to and affordability of health services has lowered thresholds for 
                                                 
1 Figure 1 is used with permission from Masoud Mirzaei. 
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diagnoses and treatment with preventive medications for hypertension and 
hyperlipidaemia (17). This has contributed to a lowered incidence of major CVD events 
and deaths compared to middle and low-income countries (17). Still, CVD is the leading 
cause of deaths in Norway; 5,975 men and 7,035 women died of CVD in 2012, 
accounting for 228/100,000 male inhabitants and 142/100,000 female inhabitants(18). 
In Europe, CVD is accounting for 42% of male deaths and 51% of female deaths (19). 
In Norway around 11–12% of patients with first acute myocardial infarction die within 
the first 30 days (20), which is a the lowest mortality rate in Europe (21, 22). 
 
2.1.1 Acute Myocardial Infarction (AMI). 
Development and diagnosis 
Atherosclerosis, the main underlying condition that leads to AMI is caused by a chronic 
systematic inflammation in the large and medium size arteries and arterial walls (23, 
24). The atherosclerotic process is strongly correlated to factors that can harm the 
endothelium such as adverse lipid profile, high blood pressure, and cigarette smoking. 
The pathological process of atherosclerosis develops over decades, beginning already in 
childhood. Initially, immune cells are attracted to support the reparation of injured sites 
in the endothelium (24). If the inflammatory response is not successful in removing the 
harmful agents, the endothelium becomes permeable for lymphocytes and monocytes 
that migrate into the deep layer of intima where they attract fatty Low-Density 
Lipoprotein (LDL) particles. The LDL particles are engulfed by the monocytes which 
forms large lipid-laden cells (foam cells) (25). The accumulation of these lipid-laden 
foam cells starts as fatty streak formation (23). This formation is the first pathological 
manifestation of the atherosclerotic process, and it is known to be reversible. As the 
atherosclerotic process is developing,  more permanent manifestations includes 
development of thickened intima, development of plaque and plaque rupture, which 
initiate the development of a thrombus. This can cause occlusion to any or several of the 
coronary or any other arteries (23). The obstructed blood flow results in oxygen 
deprivation, which leads to myocardial ischemia and necrosis (AMI). The resulting 
AMI is diagnosed by a joint assessment of clinical history of chest pain, 
electrocardiogram and elevated biochemical markers (26). Atherosclerosis is also a 
prerequisite for acute coronary syndrome (ACS), including unstable angina, AMI and 
sudden cardiac death (27). In the vast majority of cases these sudden events are caused 
by plaque rupture, intracoronary thrombus formation and abrupt blood flow reduction 
(27). 
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Prevalence of and risk factors for AMI 
AMI is amongst the most common reasons for hospitalization in Norway (28). In 2012, 
a total of 24,244 Norwegians were registered with a main diagnosis of AMI (28), which 
account for 0.6% of the 3,737,305 people in Norway aged ≥ 20 years at the time (29). 
The mean age for hospitalized patients with a main diagnosis of AMI in Norway is 68.1 
(SD 13.1) years for men and 75.9 (SD 13.2) for women (21, 28). 
Some of the most important risk factors for atherosclerosis and AMI are not modifiable, 
such as age, sex and genetic factors (14). Most other risk factors can be modified, 
including serum cholesterol, smoking habits, diabetes and hypertension (14). Also 
highly prevalent mental health conditions such as depression and anxiety symptoms are 
thought to represent such modifiable risk factors (14, 30).  
A well-known example of modifying effects stems from World War 2, during 
which the Norwegian population had scarce recourses of fatty food and sugar. This led 
to weight loss in the population (31). Additionally, access to tobacco was limited. A 
steep decline of CVD deaths occurred in the 5 year war period, and the decline was 
observable in both genders across the adult age groups. Only a small part of this decline 
could be explained by changes in CVD nomenclature from an inter-Scandinavian to an 
International diagnosis of CVD deaths,  applied by the Norwegian Statistical Central 
Bureau, in 1941 (31). In another example from Sweden, a 10.4% reduction of the 
populations’ serum cholesterol levels (from 1986 to 2006) explained 39% of the 
reduced CVD mortality in the same time-period (32). However, despite a steady decline 
in AMI mortality since the 1980s (33), still around 12.5% of all deaths in Norway are 
due to CHD (34).  
The development of effective treatment options has also improved the survival 
after AMI in high-income countries where preventive medication and revascularization 
are standard care (17). Still, there is an increased risk of stroke, sudden death and HF 
after AMI. 
 
2.1.2 Heart Failure (HF). 
Development and diagnosis of HF 
In Europe AMI is the most common index event for HF development accounting for 
approximately 60% of HF events (35). Other known precursors for HF are 
hypertension, diabetes, cardiomyopathy, valvular disease and arrhythmias (36).  
HF is defined as a syndrome characterized by elevated cardiac filling pressure 
and/or inadequate peripheral oxygen delivery, at rest or during stress, caused by cardiac 
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dysfunction (37, 38). In the development of HF, except HF initiated by AMI, the 
process of myocardial remodelling often starts long before the onset of HF symptoms 
(39). The progression of LV myocardial remodelling is a gradual and complex 
development that includes compensatory mechanisms driven forward by 
neuroendocrine activation and cytokine release (40). The remodelling process involves 
reorganization of myocytes, interstitial cells and vessels, leading to increased stiffness 
and/or impaired contractility of the myocardium (41). The HF diagnosis is often based 
on medical history and physical examination where symptoms including fatigue, 
breathlessness, ankle swelling, elevated jugular venous pressure, pulmonary crackles, 
displaced apex beat and objective evidence of cardiac dysfunction at rest plays an 
important role. The most frequently used diagnostic tests of HF include 
echocardiography, chest radiography and electrocardiography (ECG) (42). The newest 
guidelines also include measuring natriuretic peptide levels (43). 
 
Prevalence and risk factors for HF 
HF is a leading cause of morbidity, hospitalizations, disability and death across the 
world (42, 44). In Norway 30,230 (0.8% of the whole adult population) people were 
hospitalized with a main diagnosis of HF in 2012 (28). In Sweden, the estimated 
incidence of HF after adjusting for demographic variables was 3.7/1000 person years 
for women and 3.9/1000 person years for men (44). HF incidence and mortality has 
declined from 2006–2010 both in women and men. However, as HF is more prevalent 
in older age groups, the increasing longevity of the population keeps the HF prevalence 
stable (44). Elevated systolic blood pressure, impaired glucose tolerance, elevated blood 
lipids, and increased heart rate or decreased heart rate variability are strong risk factors 
for HF (45, 46). Other risk factors for HF include smoking, elevated levels of 
cholesterol, and alcohol abuse. 
 
2.1.3 Subclinical left ventricular (LV) dysfunction. 
Definition and prevalence 
Normal data for the left ventricular (LV) systolic and diastolic function have recently 
been established in several population based studies using novel echocardiographic 
techniques, such as tissue Doppler Tracking (TD) and tracking of grey-scale speckles 
(Speckle-Tracking (ST)) (47-51). Detailed information about the normal LV systolic 
reference values by age-groups and sex and ethnicity obtained by these new techniques 
are recently published by Dalen et al (2010) and the EchoNoRMAL collaborators 
(2014) (47, 50).The LV function in the normal population follows a normal distribution 
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curve. This new knowledge may serve as a tool to identify early asymptomatic LV 
impairment (subclinical dysfunction) (52), even in sub-populations with normal 
conventional echocardiography findings (53). Early interventions in people with 
subclinical LV dysfunction may help prevent progression to overt HF (38). 
Asymptomatic LV systolic dysfunction was at least twice as common as symptomatic 
HF when TD was used to identify LV dysfunction (54). This underlines the importance 
of preventive strategies at an early stage of LV dysfunction. Among the most sensitive 
TD indices in order to detect subclinical LV dysfunction is peak mitral annular early 
diastolic velocities (e´) and LV end-systolic global strain (global strain), which have 
been shown to be related to different risk factors and diseases even though other indices 
of LV systolic and diastolic function have been less influenced (55-57). 
 
Risk factors for subclinical LV dysfunction. 
Treatment of asymptomatic LV dysfunction is thought to delay or prevent the 
progression to symptomatic HF. However little is known about potentially modifiable 
precursors for LV dysfunction. Traditional risk factors for CVD, such as hypertension, 
elevated cholesterol levels and high or low body mass index (BMI) are associated with 
subclinical LV dysfunction (56), i.e. the risk factors are negatively influencing cardiac 
function years before the presentation of clinical symptoms of HF. Further, low 
educational level was associated with subclinical cardiac dysfunction and future 
hospitalization for HF in a Danish study (58). One previous study suggested that 
depressive symptoms are associated with subclinical LV dysfunction (13). However, the 
sample included people with hypertension and diabetes mellitus which might suggest 
confounding; the physical disease might have caused both the depression and the LV 
dysfunction. 
 
2.2 Anxiety and depression  
Anxiety and depression are often expressed through and subtyped into psychological, 
somatic, functional and social symptoms (59, 60). A clinical diagnostic interview, 
which assesses a great variety of anxiety and depression symptoms, is the gold standard 
and is required to assess the presence of a clinical diagnosis of depressive or anxiety 
disorders (61). In large epidemiological studies however, the use of self-report 
instruments is more cost-effective and therefore the most widely used method (62). This 
was also the case for the current study. Thus, the main emphasis will be on symptoms of 
anxiety and depression and not diagnosis. However, in order to understand the 
difference, a brief overview of some of these diagnoses will follow.  
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2.2.1 Anxiety symptoms and disorders 
Fear is a normal anxious state in the face of real danger, whilst the terms anxiety 
disorder or anxiety symptoms are often used to describe a more exaggerated, long-
standing emotional and dysfunctional state (63). The 7-items HADS-Anxiety scale 
(HADS-A) used in this thesis, includes symptom report from the last week (64). Six of 
the HADS-A items mainly capture core anxiety symptoms of restlessness and worry, 
which are also necessary in order to diagnose a person with generalized anxiety disorder 
(GAD) (65, 66). In order to meet the criteria for GAD, however, these symptoms and 
additional somatic complaints such as fatigue, irritability, sleep disturbance, muscle 
tension and difficulty concentrating, must have persisted for most days over a longer 
period of time; one month according to the Diagnostic and Statistical Manual of Mental 
Disorders (DSM) III and six months from DSM III-R and following DSM versions (66, 
67). At least one somatic symptom due to autonomic hyperarousal, such as palpitations 
sweating, trembling and dry mouth, is also essential in order to meet the diagnostic 
criteria of GAD (66). One HADS-A item assess the frequency of sudden panic during 
the last week on a Likert scale between “very often” to “not at all”. Such sudden panic 
attacks are seen in panic disorder and specific phobias when exposed to the feared 
stimulus, e.g. spiders (68). However, the diagnosis of panic disorder involves repeated 
attacks of intense fear and worry, accompanied by physical symptoms due to 
sympathetic nervous system activation, such as increased heart rate, sweating, trembling 
or shaking, dyspnoea, hyperventilation, nausea or abdominal distress or chest pain (67, 
68). Other common anxiety disorders are obsessive compulsive disorder, post traumatic 
stress disorders and social phobia (67). The severity of anxiety and depression disorders 
depends on symptom levels, persistence and functional impairment. Decreased 
functioning in social contexts, work and/or daily life activities is especially seen in 
those with moderate and severe symptom severity (67, 69). Of note, people with 
symptoms of anxiety as measured by HADS-A has been shown to be long lasting risk 
factors for onset, duration and recurrent episodes of sickness absence from work (70). 
Nevertheless, many people with anxiety disorders are able to maintain a high function 
both socially and in their jobs. Anxiety disorders in general and GAD in particular, are 
known to increase risk for subsequent depressive episodes (71, 72). In community 
samples one in three GAD patients also meet the criteria for depression and often 
patients with GAD present themselves to the doctor as depressed (73). 
 
2.2.2. Depression symptoms and disorders 
Depression symptoms are considered a normal reaction or adjustment to situations of 
great internal and/or external stress, but might represent depressive disorders if 
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symptoms persist each day for at least two weeks (74-76). Additionally, in order to meet  
the criteria for major depressive episode/disorder five out of the following nine 
symptoms must be experienced during the same two weeks; change in weight/ appetite, 
insomnia or hypersomnia, psychomotor retardation or agitation, loss of energy or 
fatigue, worthlessness or guilt, impaired concentration or indecisiveness; thoughts of 
death or suicidal ideation or attempts (77). Depressive disorders are rated as the fourth 
leading cause of disease burden accounting for 12% of years lived with disability world 
wide (78). The HADS-Depression questionnaire, which is used in this thesis, mainly 
mirrors core psychological depression symptoms during the last week; depressed mood 
or reduced pleasure response affect (anhedonia), as well as psychomotor retardation  
(64). People with depression symptoms, not only disorders, often report great functional 
impairment, e.g. high reports on the Hopkins Symptom Check list (HSC) showed high 
correlation with reduced working abilities and sleeping problems (69), and increases the 
odds of medical benefit receipt (79). Prospective studies using the HADS-D 
questionnaire has also found increased risk for disability pension (80). 
 
2.2.3 Mixed anxiety and depression symptoms (MSAD) 
Although anxiety and depression are characterized by somewhat different clinical 
features and symptoms, there is also great symptom overlap between these conditions 
(81, 82). Depression and anxiety often share functional symptoms, such as sleep 
disturbance, lack of energy and restlessness (60, 83, 84). These functional symptoms are 
prevalent also in CVD (85, 86). Further, depression and anxiety share social symptoms 
such as avoidance and social withdrawal or passiveness (60, 83). In accordance with 
this literature the HADS-A and HADS-D scales where highly inter-correlated in 
HUNT2, with a correlation coefficient 0.38 for the categorical approach and 0.51 when 
treating the scales as continuous variables (87). The overlap between anxiety and 
depression symptoms often increases with symptom severity (88-90), and mixed 
symptoms of anxiety and depression (MSAD) are often associated with poorer 
treatment outcomes and treatment response to anti-depressive medication (91), higher 
relapse incidence (92) and lower recovery rate compared to anxiety or depression alone 
(8, 93). However, the HADS depression scale is in some studies found to be more 
strongly associated with all-cause mortality than the combined effect of anxiety and 
depression symptoms (MSAD as measured by HADS-T) (94, 95).  
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2.2.4 Anxiety and depression: Prevalence and risk factors 
Mental disorders are common; studies indicate a lifetime prevalence of 25–50% and a 
12- month prevalence of 10–30% (96-98) in the western world, and anxiety and 
depressive disorders are the most common of the mental disorders.. The 12-month 
prevalence for any mood disorder was estimated to be 4.2% in the European Study of 
the Epidemiology of Mental Disorders (ESEMeD) (96) and 10.0% in the National Co-
morbidity Study (NCS) in the US. For any anxiety disorder the 12-month prevalence 
was found to be 6.4% in the ESEMeD (96) and 24.9% in the NCS (99). Both the NCS 
and the ESEMeD utilized the Composite International Diagnostic Interview (CIDI). 
However, the ESEMeD study used a new version CIDI 10, which is thought to yield 
less false positive assessments (96). Most studies find a higher prevalence of mental 
illness in urban compared to rural areas, bearing in mind that comparisons often are 
made across different studies using different instruments and methods (100). However, 
the estimated prevalence of major lifetime depression in Norway were quite similar for 
men living rurally 10.1%) compared to an urban residence (9.8%) but quite different 
when you compared between women; 19.6% prevalence in rural areas vs. 13.8% in 
urban areas (69). This estimation was calculated based on self-report on the 25-item 
Hopkins Symptom Check list (69). Thus, the prevalence of both anxiety and depression 
seems to differ considerably between different instruments and methods, study designs, 
study populations and countries. 
Comorbidity between major depression and any anxiety disorders was 51% in 
the NCS (72). In the international WHO study on psychological disorders in primary 
health care 39% of the depressed cases had anxiety disorders and 44% of those with 
anxiety disorders had comorbid depression (101). Anxiety disorders often tend to occur 
earlier in life than depression and are a powerful predictor for depression and mixed 
symptoms of anxiety and depression (MSAD) later in life (102). Such clustering of 
psychosocial risk factor may act synergistically on the risk for subsequent of physical 
disease (82). MSAD is thus often associated with more severe illness, worse outcome 
and increased mortality compared to single conditions (103). In contrast, some studies 
using the HADS have found that especially HADS-Depression is a more powerful 
predictor of all-cause mortality than MSAD as measured by the sum of HADS-D and 
HADS-A (94, 95). 
Further, depression is known to have an episodic nature (86). Recurrent major 
depressive episodes are predicted by younger age of onset, family history of depression, 
previous episodes (especially severity and duration of depression symptoms), residual 
symptoms, smoking, comorbid anxiety disorders and ongoing stress and difficulties in 
life, including substance abuse (104, 105). Limited evidence suggests that recurrent 
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depression has considerably stronger association with AMI than single depressive 
episodes (8, 106, 107). 
Risk factors for anxiety and depression symptoms are many, and below we 
highlight a few risk factors which also represent risk factors for CVD, making 
confounding by those factors possible. 
 
Sociodemograpic risk factors for anxiety and depression symptoms 
Age: Anxiety disorders often manifest earlier in life than mood disorders, often already 
in adolescence, with median age of onset at 14 years (97). Mood disorders, depression 
being the most common, have a median age of onset at 30 years (97). Kessler et al 
(2012) found that age is associated with 37% of 12-month prevalence of psychiatric 
disorders (99).  
Sex: In general, anxiety and depression disorders are more prevalent in women 
than men (98, 100, 108). One study speculated if the hormonal difference across 
genders could explain the higher prevalence (109) as the increased oestrogen-levels in  
puberty may activate a genetic vulnerability for mental health problems in females 
(110). However, the gender difference may also arise due to adaptive behavioural 
differences. Girls often take on different social roles, and have different patterns 
regarding cognition and affection towards others. But responsibility for others and 
caretaking  is also thought to result in fear of rejection and self- criticism, key features 
of anxiety and depressive disorders (110). Sex differences in childhood exposures that 
predispose for anxiety and depression is also seen, with more females being exposed to 
abuse and neglect (110). 
Marital and Socioeconomic Status: Singlehood, divorce, separation or 
widowing is associated with increased anxiety and depression prevalence (111). It is 
however, uncertain if people that are married or cohabitating have lower prevalence of 
psychiatric morbidity than the never married (111). A social class gradient is also 
observed with higher rates of mental health problems in people with lower education, 
lower income, and unemployment (111).  
 
Traditional cardiovascular risk factors and correlation with anxiety and 
depression symptoms 
The nature of the observed prospective association between anxiety and depression with 
CVD, i.e. whether anxiety and depression is a causative factor or only correlate, is 
largely unknown. Below is an attempt to present the conflicting conclusions for the 
main cardiovascular risk factors: 
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BMI. Cross-sectional data shows a positive association of depression and 
anxiety symptoms with BMI (112). A large US study (n= 177,047) found an association 
between mental health problems and BMI even when adjusting for demographics, 
psychosocial and lifestyle (113). In a large prospective follow-up study those with 
baseline anxiety and depression symptoms had larger weight change and increased risk 
of incident obesity in the follow-up period than those without anxiety and depression 
symptoms (114). The relationship is thought to be bidirectional; obesity may cause 
depression through inflammatory activity (115), social stigma or decreased activity 
(113), while anxiety and depression may also cause obesity through inactivity, binge 
eating or medication (112). Finally, common causes can lead to both increased BMI and 
depression, such as childhood abuse or bullying (113). 
Hypertension: One cross-sectional study found that high systolic blood 
pressure levels increased the odds for a high self-report scoring on the panic item in 
HADS (116). The CARDIA study pointed out that depression severity increased with 
increasing blood pressure levels (117), yet the trend for anxiety severity did not reach 
statistical significance (p 0.09). One prospective follow-up study found that high 
symptom levels of anxiety and depression predicted lower blood pressure at follow-up 
(118). Conversely, another prospective follow-up from 19 countries found that both 
mood and anxiety disorders were risk factors in a dose-response manner for subsequent 
hypertension (119). However, the authors pointed out that important confounders for the 
observed risk could be alcohol, over-eating or a poor diet rich in salt and animal fat. 
Childhood abuse could also be common cause for both the mental disorders and 
hypertension (119). 
Alcohol: Alcohol use may increase the risk of major depressive disorder and 
recent alcohol use and major depression is also strongly associated (120). Alcohol is 
often used as self-medication in persons with psychiatric disorders as it is associated 
with a temporarily alleviation of the anxiety and depression symptoms (121) and 
initially, alcohol enables sleep (122). 
Smoking: Depression and anxiety disorders are associated with higher rates of 
cigarette smoking than the general population (115, 123, 124). It seems that smoking 
often is used to diminish negative effect associated with depression and anxiety 
symptoms (124). Nicotine initially increases dopamine levels, which engage feelings of 
reward. However, long term nicotine use decreases the dopamine levels (125). It is still 
unclear if depressive behaviour increases smoking or if cigarette smoking increases 
depression symptoms (115) even though two genetic study found no signs of a causal 
role of smoking in the development of depression and anxiety (126, 127).  
Inactivity: People with anxiety and/or depression symptoms have greater odds 
of not meeting the recommended levels of exercise (128). However, the relationships 
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are bidirectional and regular activity also has the potential to decrease the risk for 
anxiety and depression symptoms (128, 129). In regards to underpinning mechanisms, 
physical inactivity may also explain some of the increased risk that is observed between 
poor diet and depression (130). 
All the above described cardiovascular risk factors associated with depression 
and anxiety symptoms are associated with inflammatory activity and release of 
proinflammatory cytokines (115), which in turn are  important drivers in the 
atherosclerotic process . Both anxiety and depression symptoms further represent a 
disorder of hyperarousal accompanied by a chronic activation of the stress response 
with increased activity in the hypothalamic-pituitary-adrenal axis (HPA) and the 
sympathetic nervous system (131). This stress reaction may lead to raised concentration 
of circulating catecholamine in the blood, leading to physiological changes such as 
increased heart rate, decreased heart rate variability, increased blood pressure, coronary 
vasoconstriction and increased platelet activity (131, 132).  
 
Comorbid physical illness in anxiety and depression 
Few studies have assessed the impact of anxiety disorders on function and outcome in 
physical illness (133). Several studies have shown that there is increased prevalence of 
major depression in people with chronic physical diseases, such as asthma, arthritis, 
diabetes and cancer (2, 78, 85, 86, 134, 135). Anxiety disorders are shown to be more 
prevalent in irritable bowel syndrome, asthma, cancer and CVD (133). Depressive or 
anxiety disorders that are comorbid with physical illness is suggested to cause greater 
decrements to health than each condition alone, i.e. there are signs of an interactive 
effect (78, 133). Of note, when inflammatory cytokines are released due to somatic 
disease, they are also shown able to induce depressive-like behaviour and symptoms, 
such as anhedonia, fatigue, anorexia and reduced social interaction (136, 137). 
Depressive symptoms especially are highly correlated with the overall disease burden 
from physical illness, and several common chronic disorders are also risk factors for 
AMI. As a result these are potential confounders.  
 
2.3 Anxiety and depression symptoms in AMI, HF and subclinical LV dysfunction  
Anxiety and depression disorders are highly prevalent conditions in people with 
established CVD. Up to 20–40% of patients with CHD (132, 138, 139) and up to 70% 
of hospitalized HF patients suffer from comorbid depression (140-142). Evidence is 
strong for increased morbidity and mortality when anxiety and/or depression disorders 
coexist with established CVD (30, 86, 141, 143-147). However, the causal relation 
between depression and anxiety symptoms with excess risk for mortality and morbidity 
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in established CVD is not agreed on (148). Mainly three causal pathways between 
depression symptoms and established CVD are mentioned; 1) depression symptoms 
may act like a marker of CVD disease severity; 2) shared risk factors such as smoking 
and inactivity explains both the CVD and the anxiety and depression symptoms; 3) a 
bidirectional relationship where the depression and CVD exerts direct effects on each 
other (148).   
Meta analyses have found an increased CVD risk associated with anxiety and 
depression symptoms in initially healthy persons (3, 4). More specifically, results from 
prospective studies suggest that anxiety and depression disorders and symptoms are risk 
factors for future AMI (5, 149-154) and HF (155-157). One cross-sectional study has 
found association between depression symptoms and subclinical LV dysfunction (13). 
Previous studies cannot conclude to what extent the well-known cardiovascular risk 
factors explain the observed associations between mental health and CVD (3, 150). One 
meta-analysis of 54 observational studies showed a paucity of adjustments for even the 
well-known cardiovascular risk factors such as smoking and physical activity (3). This 
was found in most studies of the risk between depressive disorders or symptoms and 
future AMI (3).  
Comorbid physical disorders are among the most overlooked confounders 
between mental health and CVD (85, 86). Especially depressive disorders and 
symptoms are highly correlated with the overall disease burden (85), and several 
common chronic disorders represent individual risk factors for AMI, HF (38, 158) and 
development of subclinical LV dysfunction (56). In the only previous study we found 
studying the association between depression symptoms and LV dysfunction, the sample 
included people with hypertension and diabetes, diseases known to be associated with 
depression (134). Thus the observed association between LV dysfunction and 
depression may be due to confounding from medical comorbidity.  
Moreover, some studies suggest that recurrent depressive disorders have 
considerable stronger association with AMI than single depressive episodes (8, 106), yet 
the majority of studies assessed depression at one time-point only (159). To the best of 
our knowledge, no studies exist for recurrent depression symptoms and risk of HF and 
subclinical LV dysfunction. Still, relative little data are available on the prospective 
association between anxiety and risk of CVD, and similar methodological issues as 
those presented for depression apply to these studies as well (160).  
The nature of the causal direction in these associations still remains 
controversial. One of the most challenging issues on the prospective association of 
anxiety and depression with CVD is reverse causality. One example is atherosclerosis, 
one of the main underlying pathophysiological mechanisms of AMI, which is known to 
develop over decades before presentation of the first clinical symptoms (159, 161). 
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However, almost all studies of depression and CVD risk included mainly middle aged 
or older adults, often with a short follow-up time (3, 155, 156, 162, 163). Thus, 
individuals free from clinical heart disease in the aforementioned prospective studies 
may not be free from atherosclerosis, which may facilitate depressive symptoms even 
before generating ischemia (161, 164). In HF, except HF initiated by AMI, the process 
of myocardial remodelling also starts long before the onset of HF symptoms (165). 
Some of the processes that contribute to the progression of HF, such as like pro-
inflammatory cytokines (140), are known to give depression as well (115). 
 
2.4 Aims  
The main aims were to investigate the association between single and repeated measures 
of anxiety and depression and mixed anxiety and depression symptoms (MSAD) with 
future AMI (paper I), future HF (paper II) and present subclinical LV dysfunction 
(study III), controlling for potential confounders, including comorbid physical illnesses 
in a large population-based cohort. 
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3.0 Methods 
3.1 Study setting, sampling and design 
This thesis is based on data from the Nord-Trøndelag Health Study, 
http://www.ntnu.edu/hunt (166-168). Paper I and II additionally utilize endpoints for 
AMI and HF from the Hospital Registries in Nord-Trøndelag County and the National 
Cause of Death Registry.  
Nord-Trøndelag County is located in the central part of Norway (Figure 2) and has 24 
administrative municipalities (167). Around 127,000 people live in the county and net 
migration was about 0.3% per year in the period 1996-2000. In most respects, such as 
age distribution, morbidity and mortality, Nord-Trøndelag County is a relatively 
representative sample of the Norwegian population. There are two hospitals in the 
county, located in Levanger and Namsos. Both hospitals are managed by Nord-
Trøndelag Hospital Trust (HNT), and these two hospitals serve the entire population in 
the county. 
 
Figure 2: Map of Norway and Nord-Trøndelag County 
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3.2 The HUNT Study 
HUNT is a population based general health survey and has to date been carried out in 
three waves. HUNT1 was conducted in 1984–86 (166), and new waves were carried out 
in 1995–97 and 2006–2008 (167, 168). In all three surveys the entire adult population 
(aged ≥ 20 years) was invited to participate. The participation rates have generally been 
decreasing, but compared to most epidemiologic studies the participation rate is overall 
high. Additionally, many of the subjects have participated in more than one of the 
waves. Table 1 displays the eligible population and participation in HUNT1–3.  
 
Health Survey HUNT1 HUNT2  HUNT3 
Year   1984–86 1995–97 2006–2008 
Invited 86,404 94,187 93,860 
Participated n, (%) 77,212 (89.4%) 65,212 (69.2%) 50,807 (54.1%) 
Participated in previous HUNT , n  N/A 47,316 (HUNT1) 37,071 (HUNT2) 
Table 1: Invitation and participation in HUNT1-3 
 
All HUNT waves were approved by the National Directorate of Health and the 
Norwegian Data Inspectorate. All participants gave written consent before the baseline 
examination. Additional approval was given from the regional ethics committee and the 
HUNT data access committee for all three studies presented in this thesis. 
All three studies included standardized clinical examinations performed by 
trained nurses, self-report on health related questionnaires 
http://www.ntnu.edu/hunt/data/que. In addition HUNT2 and HUNT3 collected blood 
samples from all participants (167, 168). The self-report questionnaires were extensive, 
and were distributed in a two-step procedure. Questionnaire 1 (Q1) was delivered by 
post together with a personal invitation to participate. The participants would fill in Q1 
at home and bring it to the clinical examination. At the examination the attendees 
received Questionnaire 2 (Q2), which was taken home, filled in and returned in a 
prepaid envelope. The respondent rate was higher on Q1 than Q2 in all HUNT waves 
(169).  
3.3 Study variables  
Information on the clinical end-points (AMI in paper I and HF in paper II) were 
collected from the two hospitals in the county and from the National Cause of Death 
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registry. All other data came from the HUNT study. Table 2 provides an overview of 
the sources of data used in the three studies.  
 
Study Baseline (clinical 
examination, 
laboratory data and 
self-report) 
Anxiety and depression 
(self-report) prior to 
baseline 
Outcome 
I–II HUNT2 (1995–97) HUNT1 (1984–86) Hospital and Cause of 
Death Registry  
(1995–2009) 
III HUNT3 (2006–2008) HUNT2 (1995–97) Echocardiography 
recordings (HUNT3) 
Table 2: Overview of sources of data extraction in the different studies 
 
3.3.1 Questionnaires  
Anxiety and depression symptoms; The HADS Scale (all studies) 
The Norwegian version of the HADS was available from Q1 in HUNT2 and 
from Q2 in HUNT3. The HADS instrument was originally developed by Zigmund and 
Snaith in 1983 to separate depression and anxiety symptoms from the symptoms caused 
by somatic illness (64). Functional and somatic symptoms of depression and anxiety 
that could be related to somatic diseases, such as fatigue, insomnia, dizziness were 
therefore not included in the scale. The HADS consists of two subscales, which assesses 
symptoms of anxiety (HADS-A) and depression (HADS-D) during the previous week. 
The 7 anxiety questions mirror symptoms of worry and restlessness, while the 7 
depression items mirror core psychological depression symptoms of reduced pleasure 
response (anhedonia), depressed mood and psychomotor retardation. All questions have 
a 4-point Likert scale response option from 0 (no symptom) to 3 points (highest level). 
Both subscales thus range from 0 (no symptoms) to 21 points (highest symptom level). 
The HADS has shown good psychometric properties across various patient samples and 
settings (170). 
Valid HADS response was defined as completed answer on 5 or more items on 
each subscale. Missing responses amongst those who filled in five or six items were 
replaced based on the sum of completed items multiplied by 7/5 or 6/5, respectively. 
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Operationalization of the HADS-D and HADS-A scores 
In paper I and II we made an a priory decision about categorizing the participants 
according to their HADS-D and HADS-A scores, respectively, as having no symptoms 
of depression or anxiety (score <8), mild to moderate symptoms (score 8–10) and 
moderate to severe symptoms (score ≥11) (64). In paper II, the HADS-D and HADS-A 
variables were analysed as continuous variables, in addition to the categorical approach. 
In study III, the number of people whom scored above 8 and 11 on HADS-D and 
HADS-A were very few. Thus the HADS was treated solely as a continuous variable in 
the analysis. 
In paper I and II, a combined HADS total score (HADS-T) for assessing the 
impact of mixed symptoms of anxiety and depression (MSAD) was calculated by the 
sum of valid HADS-A and HADS-D scores. In the literature, a wide range of different 
HADS-T cut-offs have been used (170). We categorized the participants into three 
groups: no MSAD (score <15), mild to moderate MSAD (score between 15 and 18) and 
severe MSAD (score ≥19) The latter cut-off was associated with psychiatric help-
seeking, self-report of lifetime major depressive disorder, daily impairment because of 
lifetime mental problems and with having chronic somatic disease in a 4 year follow-up 
study arising from the HUNT population (171). 
 
Repeated anxiety and depression symptoms  
Many of the HUNT participants had participated in more than one wave of the 
study. This enabled us to assess whether two incidents of elevated anxiety and 
depression symptom scores, ten years apart, increased the risk for AMI, HF and 
subclinical LV dysfunction, compared to high levels in one wave only or normal levels 
at both waves.  
 
Anxiety and depression symptoms prior to HUNT 2, (paper I and II).  
HUNT1 (Q1) used a crude 4-item Anxiety and Depression Index (ADI-4), which is not 
suitable to distinguish between anxiety and depression. ADI-4 showed a high 
correlation (0.83) with the HADS-T score in HUNT2 and is an acceptable indicator for 
MSAD (sensitivity 0.51, specificity 0.93) (172) in our studies. 
Two ADI questions have a 4-point Likert Scale; calmness ranging from almost 
all the time (1) to never (4) and nervousness ranging from never (1) to almost all the 
time (4). The last two ADI questions about mood and vitality have a 7-point Likert scale 
ranging from very happy/ strong and fit (1) to very downhearted/tired and worn out (7). 
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A variable to indicate the combined burden of MSAD in HUNT1 and 
HUNT2 was created in three categories of never, one or two episodes. MSAD in 
HUNT2 was defined as cut-off ≥19 on the HADS-T scale. Episode of MSAD in 
HUNT1 was defined by scoring in the upper quartile on ADI, i.e. a cut-off at ≥14 
points. “Never MSAD” was defined as a scoring <14 on ADI in HUNT1 and <19 on 
HADS in HUNT2. “MSAD once” was defined as scoring above cut-off in one of the 
studies, while “MSAD twice” included those scoring above cut-off in both studies.  
 
Anxiety and depression symptoms prior to HUNT3 (study III).  
We treated the HADS scales from HUNT2 and HUNT3 as continuous 
variables and added each participant’s HADS-D and HADS-A scores in order to assess 
risk with additive symptom levels from two waves.  
 
Demographic and sosioeconomical variables 
Education was categorized as low (≤9 years), medium (10 to 12 years) or high 
(>12 years) level (all studies).  
Cohabitation status was dichotomized as living with a partner or alone in paper 
I and II. In study III cohabitation status was categorised into never married, married or 
living with partner, or separated/divorced/widowed.  
Common chronic disorders (paper I and II). Participants self-reported if they 
had (or had ever had) cancer, asthma, diabetes mellitus, other endocrine disorders 
(hypothyreosis, hyperthyreosis, goitre and thyroiditis), musculoskeletal disorders 
(osteoporosis, fibromyalgia, and arthrosis/arthritis), autoimmune disease (Bechterew 
disease, rheumatoid arthritis), epilepsy or any other chronic disorders. 
 
Life style factors  
Smoking habits were self-reported and categorized as current, previous or 
never smoking (all studies).  
Physical activity was defined as light if it didn’t involve sweating or feeling of 
breathlessness, while hard physical activity was defined by sweating or breathlessness. 
In paper I and II the participants were categorized as inactive (less than 1 hour of hard 
activity and less than 3 hours of light physical activity per week), moderately active (1–
3 hours of hard activity or >3 hours of light activity per week), and as physically active 
(>3 hours of hard physical activity per week). In study III, we used a validated index for 
leisure-time physical activity, calculated as a product of exercise frequency, exercise 
intensity and training session duration (173). 
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Alcohol (paper II) was categorized as abstainers, very light drinkers (0–1 drinks 
per day), light to moderate drinkers (1–2 drinks per day) or moderate to heavy drinkers 
(>2 drinks per day). 
 
3.3.2 Clinical examination 
Trained nurses performed the clinical examinations at baseline after a standardized 
protocol in all three HUNT waves (166-168).  
Systolic and diastolic blood pressures (all studies) were measured three times 
after the participant had been seated for at least two minutes with the cuff on, with cuff 
size adjusted for arm circumference. All blood pressure measurements were performed 
with the Dinamap 845XT (Criticon) based on oscillometry. The average of the second 
and third measurement was used in the analyses. 
Heart rate was measured using the above described Dinamap (paper I and II). 
The first heart rate recording was in average two beats per minute (bpm) lower than the 
second and third measurement and was thus used in order to mirror resting heart rate. In 
study III, we used the average heart rate during echocardiography as recorded by the 
high-end scanner (Vivid 7, version BT06; GE Vingmed Ultrasound AS, Horten, 
Norway).  
Body mass index (BMI) (all studies) was computed as weight (in kg) divided by 
the square of the height (in meters). Height was measured without shoes to the nearest 
1.0 cm and weight with light clothing to the nearest 0.5 kg. 
3.3.3 Laboratory measurements  
A non-fasting whole blood sample was drawn from each participant, and the time 
between last meal and the venepuncture was recorded. Serum was separated by 
centrifugation at the screening site and immediately placed in a refrigerator (4°C). The 
samples were sent (same day or following Monday for samples drawn on Friday) for 
analyses at the central laboratory at Levanger Hospital, Norway, where they used a 
Hitachi 911 Autoanalyzer, applying reagents from Boehringer Mannheim, Germany. 
Serum total cholesterol (paper I and II) was measured by an enzymatic 
colorimetric cholesterol esterase method. The day-to-day coefficient of variation for 
total cholesterol was 1.3% to 1.9% (167).  
Serum creatinine (paper II) was measured by the Jaffé method, and the day-to-
day variation was on average 3.5% (167).   
 
23 
 
3.3.4 Definition and ascertainment of CVD (HUNT2, papers I and II). 
Among the people that participated in HUNT2 some had experienced CVD events prior 
to baseline, and these were excluded from our studies. In paper I we excluded people 
with previous history of CVD; that is previous AMI, self-reported angina or stroke (n= 
4,734). In paper II we excluded people with previous HF (n=126). After participating at 
the baseline examination in HUNT2, the participants were followed up for a first AMI 
(paper I) and incident HF (paper II) until December 31, 2008, by linkage with medical 
records in the two hospitals in Nord-Trøndelag County or by death certificates from the 
National Cause of Death Registry.  
AMI was diagnosed according to the European Society American College 
Cardiology Consensus Guidelines (26, 174). Criteria for AMI included: (1) Certain 
symptoms according to case history information, (2) specified changes in the blood 
levels of cardiac enzymes and (3) specified ECG changes (26, 174, 175). The hospital 
AMI diagnosis is found to be approximately 100% correct according to the guidelines 
(176). Deaths from AMI were defined as ICD codes no 410 in the 9th revision and 
codes I21 and I22 in the 10th revision.  
Hospital criteria for HF was defined and diagnosed according to the current 
European Society of Cardiology Guidelines (177). Criteria for HF included symptoms 
and signs of HF and additionally echocardiography, radiological examination and 
biochemical measurements. The overall quality of the hospitals discharge diagnosis of 
HF is generally high in Nordic countries (178, 179). In order to increase specificity we 
only extracted primary hospital diagnoses as recommended (178). Deaths from HF were 
defined as ICD-9 code 428 and ICD-10 codes I50.0, I50.1 and I50.9.  
 
3.3.5 The echocardiography study (HUNT3, study III). 
Within the HUNT3-study, the Echocardiographic study was conducted in a random 
selection of 1,296 subjects free from known CVD, diabetes or hypertension. The 
random selection process took place when the participants attended a baseline clinical 
examination at the study centres and the echocardiographic examinations were 
performed at this visit. Thirty individuals were excluded from the normal reference 
population due to echocardiographic findings that could interfere with LV function, and 
thus, 1,266 healthy subjects were included in the analyses. 
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Acquisition, analyses and reproducibility of the echocardiography study. 
All echocardiography examinations were conducted by an experienced cardiologist 
(HD) and the participants were examined in the left lateral decubitus position with a 
high-end Vivid 7 scanner (version BT06; GE Vingmed Ultrasound AS, Horten, 
Norway) using a phased-array transducer (M3S and M4S). All the presented 
echocardiographic measurements were available in ≥ 96% of the random selection 
(180). All echocardiographic data were stored digitally and analysed subsequently (50, 
56, 180, 181).  
Left ventricular (LV) function was assessed by several well-established 
echocardiographic indices of systolic and diastolic longitudinal function. The LV end-
systolic global strain (global strain) refers to percentage longitudinal shortening of LV 
myocardium during systole, and LV peak global strain rate (global strain rate) reflects 
the maximal speed of global strain. Both indices are presented as the average of 
segmental values when assessed in a 16 segment model of the LV (180). We used 
customized software (GcMat; GE Vingmed Ultrasound, Norway) with a combination of 
Tissue Doppler (TD) for tracking along the ultrasound beam and Speckle Tracking (ST, 
trace grey-scale speckles) for tracking perpendicular to the ultrasound beam (56).  
Peak mitral annular systolic velocity (S’) and peak mitral annular early 
diastolic velocities (e’) were measured in the base of the LV wall by pulsed waved TD 
and the average of the septal, lateral, anterior, and inferior locations was used in the 
analyses. Correspondingly, mitral annular plane systolic excursion (MAPSE) was 
measured as the average of the total systolic cumulative excursion of the same locations 
Ejection fraction (EF) was analysed by calculation of end-diastolic and end-systolic LV 
volumes from tracings in the four and two chamber view (56).  
The reproducibility of the echocardiographic measures has been described 
elsewhere by Thorstensen et al (2010) (181). Briefly the inter-observer mean errors 
were 4–8% and intra-observer mean errors were 2–5% for indices of LV function (56). 
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Figure 3 2below depicts; A) 4-chamber view where regions of interest are 
localized at the segmental borders of the left ventricle in the customized software 
(GcMat; GE Ultrasound) with a combination of tissue Doppler for tracking along the 
ultrasound beam (orange boxes) and speckle tracking for tracking perpendicular to the 
ultrasound beam (white boxes). B) End-systolic strain refers to average of segmental 
strain in a 16 segment model of the left ventricle. Strain is calculated as the percentage 
systolic longitudinal shortening of myocardial segments (difference between L0 and L) 
in a segmental model of the LV myocardium during systole. C) Strain curves for the six 
segments shown in A. D) Zoom in of basal and mid-ventricular segments of the septal 
wall with end-systolic strain values. Blue curves are segmental values, green curves 
illustrate the average value.  
 
 
 
Figure 3: A: 4 chamber view of regions of interest. B: End systolic strain. C: Strain 
curves. D: Strain curves. 
                                                 
2 Fgure 3 is made by Håvard Dalen, January 2015. 
26 
 
3Figure 4 illustrates; A) The left ventricle as shown in a 4-chamber view. Red lines 
perpendicular to the ultrasound beam (measured at *) illustrate the sampled volume for 
Tissue Doppler assessed myocardial velocities located at the basal part of the septal 
wall. B) Tissue Doppler velocity curve assessed from the same region as illustrated 
above. ECG is shown as green line at bottom. Measurements of peak mitral annular 
systolic (S’), early diastolic velocities (e’) (and late (atrial (a’)) diastolic velocity) are 
marked by arrows. 
 
Figure 4: A) The left ventricle in a 4 chamber view. B) Tissue Doppler velocity curves. 
                                                 
3 Figure 4 is made by Håvard Dalen, January 2015. 
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3.4 Statistical analyses. 
All statistical analyses were conducted with Stata IC/12.1 for windows (© Stat Corp 
LP). 
3.4.1 Prospective analysis (papers I and II). 
Comparisons among those who developed AMI (paper I) and HF (paper II) during 
follow-up and those who did not were made by two-sided t-test for continuous 
variables, and χ2 test for categorical data.  
We used Cox proportional hazard models to examine the association of 
depression and anxiety symptoms and subsequent risk for AMI (paper I) and HF (paper 
II). We calculated hazard ratios (HRs) and 95% confidence intervals (CIs). Paper II 
estimated the risk per unit increase on the different HADS-scores. Both articles 
categorised the anxiety and depression symptoms and the highest categories, i.e. ≥ 11 on 
each scale, were compared with the rest of the categories. For test of trends, we assigned 
a numeric value of 0 to 2 to the HADS categories, with 0 having no, 1 having moderate 
and 2 having severe anxiety or depression symptoms, treating the categories as a 
continuous variable. In a separate analysis, we calculated the risk for AMI (paper I) and 
HF (paper II) associated with the presence of MSAD in HUNT1 and HUNT2 when 
those without symptoms of MSAD in both of the surveys constituted the reference 
group.  
The associations between symptoms of anxiety and depression with AMI 
(paper I) and HF (paper II) were assessed in different multivariable models. We 
included sex and age as potentially confounding factors in our models. In model 2 
education and marital status were added in order to adjust for potentially socioeconomic 
confounders. Established cardiovascular risk factors such as resting heart rate, high 
blood pressure, low physical activity, high BMI, smoking, dyslipidaemia, diabetes 
mellitus, serum-creatinine (paper II), and alcohol intake (paper II) may act both as a 
confounding and mediating factors for the association of anxiety and depression 
symptoms with cardiovascular risk. We therefore modelled the data both with (model 3) 
and without (model 1 and 2) these factors in the analyses. In paper II we also tested 
whether AMI prior to baseline (model 4) and AMI during follow-up (model 5) 
influenced our estimates of the association of anxiety and depression with HF. AMI 
during follow-up was included as a time-dependent variable. 
We conducted several stratified analyses to assess whether the association of 
anxiety and depression and risk for AMI could be modified by other factors. We 
investigated the potential effect modification by sex, age (dichotomized at age 50 and 
age 65), body mass index (BMI; dichotomized at ≥ 35 kg/m2), total cholesterol 
(dichotomized at 6.5 mmol/L), education (dichotomized at 12 years), blood pressure 
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(systolic blood pressure dichotomized at >140 mm Hg, diastolic at >90 mm Hg), 
smoking status (current versus no current smoking), alcohol consumption (paper II; 
heavy drinking/no heavy drinking) and previous AMI (paper II yes/no). We also 
formally tested the homogeneity of stratum-specific relative risks. For these tests of 
interaction, we used the trend variable as defined above.  
We performed several sensitivity analyses to assess the robustness of our 
findings. In paper II we analysed the risk restricted to diabetic patients. In both papers 
we excluded participants with cancer, asthma, diabetes mellitus, other endocrine 
disorders, musculoskeletal disorders, and autoimmune diseases or other reported 
chronic disorders and repeated the Cox analysis in the population without chronic 
disease. We also restricted the analysis to AMI cases (paper I) and HF cases (paper II) 
that were confirmed at the hospital, thus cases whose AMI/HF diagnosis were based on 
death certificates alone were excluded from the analyses. Finally, in order to address the 
possibility of reverse causation as an explanation for possible associations, we excluded 
the first five years of follow-up and repeated the analyses. All sensitivity analyses were 
run in the full multi-variable model (paper I: model 3; paper II model 5).  
We tested the proportionality of hazard using log-log curves and formal tests of 
interaction with time or log-time. There was no evidence against the proportionality 
assumption in our models. 
3.4.2 Cross-sectional analysis (study III). 
Clinical echocardiographic data followed a normal distribution and is presented as mean 
(SD). Characteristics by gender is presented as mean (SD) for continuous variables and 
as numbers (%) for categorical data. Associations of symptoms of depression and 
anxiety with LV function were estimated by multivariate linear regression analyses with 
the different LV function indices as dependent variables as all LV function indices were 
mutually correlated (r 0.21–0.61, all p<0.001). The LV function measures were log 
transformed, and the partial-regression coefficients are presented as the percentage 
difference in LV function per specified 5 units difference in HADS-score with the 
corresponding 95% confidence intervals.  
Spearman correlations were performed between all HADS-scores and LV 
function data. All our linear regression models were adjusted for age and heart rate 
during echocardiography as a potentially confounding factor for the association of 
depression symptoms with cardiac function. In model 2, we added potential 
socioeconomic confounders (education and marital status), and in model 3 established 
cardiovascular risk factors such as blood pressure, BMI, smoking and physical activity 
index were included. We investigated the potential effect modification by sex and age 
(dichotomized at age 50). We found signs of effect modification of gender with global 
strain (p=0.019), thus we stratified all our analysis by sex.  
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We tested our models for violations of linear assumptions, including variance 
and normally distributed residuals, and the linear fit was tested with and without 
polynomials. We found no serious violations for using the linear line approach. 
3.5 Ethical considerations. 
All the studies were approved by the Norwegian Directorate of Health, the Norwegian 
Data inspectorate, the Regional Committee for Medical Research Ethics and the Data 
Access Committees at HUNT and HNT.  
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4. Main Results 
4.1 Paper I: “Symptoms of anxiety and depression and risk of myocardial 
infarction: the HUNT 2 study”. 
In paper I, we examined the prospective risk associated with anxiety and depression 
symptoms and future risk of first incident AMI. Baseline data on anxiety and depression 
symptoms, sociodemographic variables, health status including cardiovascular risk 
factors and common chronic disorders were registered for 57,953 adult men and women 
free of cardiovascular disease.  
Results: The cohort was followed up during a mean (SD) 11.4 (2.9) years for a first 
AMI from baseline, through 2008. A total of 2,111 incident AMIs occurred either 
identified at hospitals or by the National Cause of Death Registry. The multi-adjusted 
hazard ratios (HR) were 1.31 (95% CI 1.03–1.66) for severe symptoms of depression 
and 1.25 (95% CI 0.99–1.57) for anxiety. Two episodes of mixed symptoms of anxiety 
and depression (MSAD), reported ten years apart, increased the risk of AMI by 52% 
(95% CI 1.11–2.08). After exclusion of all AMIs occurring during the first five years of 
follow-up, the association of severe depression symptoms with AMI risk attenuated to a 
HR of 1.14 (95% CI 0.83–1.57). Relative risk for AMI with severe anxiety symptoms 
and MSAD weakened to 1.14 (95% CI 0.74–1.75) and 1.38 (0.79–2.40), respectively, 
when participants with chronic disorders were excluded. 
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4.2 Paper II: “Symptoms of anxiety and depression and risk of heart failure; 
the HUNT study.” 
 In this HUNT2 study 62,567 adult men and women free of known HF, were included.  
Results: The cohort was followed for incident HF from baseline throughout 2008. A 
total of 1,499 cases of HF occurred during a mean follow-up of 11.3 years (SD= 2.9), 
either identified in hospital registers or by the National Cause of Death Registry. We 
found no excess risk for future HF associated with symptoms of anxiety symptoms or 
MSAD at baseline. Risk with two episodes of MSAD in both HUNT1 and HUNT2 was 
associated with a HR of 1.47 (95% CI 1.04–2.01) which was partly explained by AMI 
before follow-up (HR 1.21, 95% CI 0.76–1.93). For depression symptoms, the multi-
adjusted hazard ratios for HF were 1.07 (95% CI 0.87–1.30) for moderate symptoms 
and 1.41 (95% CI 1.07–1.87) for severe symptoms (p for trend 0.026). Established 
cardiovascular risk factors, AMI prior to baseline and adjustment for incident AMI as a 
time-dependent covariate during follow-up had little influence on the estimates. The 
evidence for a dose-response relationship between depression symptoms and future was 
confirmed in the analysis using the risk per unit HADS score, and we found no evidence 
of effect modification due to reverse causality or confounding from common chronic 
disorders.  
  
33 
 
4.3 Study III: “Cardiac function and symptoms of depression and anxiety in 
a healthy population. The HUNT study”  
 
In study III we examined the associations of single and repeated self-reported 
depression and anxiety symptoms on the Hospital Anxiety and Depression Scale 
(HADS) with sensitive indices of LV systolic and diastolic function based on Tissue 
Doppler (TD) and Speckle Tracking (ST) in a healthy population. The study originated 
from the third wave of the Nord-Trøndelag Health Study. A random selection of 1266 
persons who where free from known cardiovascular disease, hypertension and diabetes 
at baseline underwent echocardiography. In the echocardiography population 1034 had 
filled in the HADS questionnaire in HUNT3, and 700 of them had participated and had 
valid HADS responses in HUNT2 (1995–1997) ten years earlier.  
Results: Baseline depression and anxiety symptoms were not associated with a 
reduction in LV indices in HUNT3. However, a 5 unit increase in the additive HADS-D 
scores from HUNT2 and HUNT3 but not the additive anxiety symptoms, where 
associated with a reduction in early diastolic annular velocity (e´); -5.5% (95% CI -9.6,-
1.5) for women and -5.0% (95% CI -8.6, -1.3) for men. 
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5 Discussion 
 
The main findings in this thesis are: 
x Self-reported symptoms of depression and anxiety, especially if recurrent, 
were moderately associated with risk of incident AMI. Results indicate that 
these associations might partly reflect reverse causation or confounding from 
common chronic diseases. 
x Depression symptoms but not anxiety or MSAD, were associated with 
increased risk for HF in a dose-response manner. The increased risk could 
not be fully explained by cardiovascular or socioeconomic risk factors, or by 
comorbid AMI.  
x The additive sum of depression symptoms from HUNT2 and HUNT3 were 
associated with lower LV diastolic function measured by echocardiography 
among healthy participants in HUNT3.  
5.1 Strengths and limitations 
Below we discuss the methodological strengths and limitations of the thesis, especially 
the typical sources of error relevant to epidemiological studies.  
5.1.2 Random error 
The observed associations in epidemiological studies may be due to chance or 
unexplained variability in data (182). Random error in epidemiological data can be 
caused by any factors that randomly affect the data, like sampling error, biological 
variation or measurement errors (182). The opposite of random error is precision (182) 
and the measure of precision in studies I–III is the 95% confidence interval (CI). A large 
sample size is a preferred way to reduce random error and thus increase precision in an 
epidemiological study (182). Paper I and II both include very large sample sizes 
compared to most prior research in this field, with over 57,000 persons included in each 
study. The large sample size in these studies also allowed us to perform sensitivity 
analysis in sub-groups of the sample. Study III describes a study performed in a in a 
random subsample (n=1,266) of the HUNT3 population. As a consequence, some of the 
effect measures, especially in the 700 persons that had valid anxiety and depression 
scores from HUNT3, were less precise as illustrated by wide CIs. 
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5.1.3 Validity (lack of systematic error) 
Internal validity  
The presence of systematic errors may lead to incorrect results. Little systematic error 
reflects high internal validity and if so, the internal validity will not improve 
significantly by increasing the sample size. There are three types of systematic errors, 
which need to be carefully considered in study design and analysis: selection bias, 
information bias and confounding (182).  
Selection bias is a distortion that results from erroneous selection of the 
participants in the study (182). That is, a selection bias would occur if the participants 
had a different association between the exposure, i.e. anxiety and depression symptoms 
and  the outcome, i.e. CVD, than those who in theory could have been eligible(183). 
The HUNT2 study, baseline for paper I and II, had an overall high participation rate of 
71.2% (167, 169). However, the attendance rate differed between age groups and the 
participation rate was lowest among the age group 20–29 (49%) (167, 169).  The HUNT 
2 non-participation study showed that health related mechanisms were unlikely reasons 
for not participating in the younger age groups (167). Thus it is unlikely that we would 
have gained different results by recruiting more young people. More importantly, the 
age groups 40-79 had a very high participant rate of 77–85% and our Cox models did 
not show a potential effect modification by age. 
The follow-up period (paper I and II) may also potentially introduce selection 
bias in prospective studies, as health related conditions often lead to an inability to 
continue the participation (182). However, loss of follow-up in this study is minimal 
due to; 1) use of health registries which track the individuals disease profile by a unique 
11 digit identification number given to each Norwegian citizen at birth; 2) the 
population in Nord-Trøndelag has a high residential stability (less than 0.3% net 
migration/year) (167), which ensure that we find most of the participants diagnosis in 
the hospital registries and; 3) data from Statistics Norway allows us to censor those few 
who moves out of the county.  
In HUNT3 (study III) the attendance rate dropped to 54%, and a separate non-
participating study was carried out (184). This study showed that depression symptoms, 
and to a lesser degree anxiety symptoms, were more prevalent in non-participants than 
participants (184). Further studies should include more patients with higher burden of 
anxiety and depression symptoms in order to evaluate the influence on LV function in 
such a population. 
Information bias occurs due to systematic errors in measurements of exposure, 
covariates or in classification of the outcome variables. The measurement error can be 
differential or non-differential (182). 
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Differential misclassification occurs if the misclassification of the exposure 
depend on the outcome (or vice versa) and can lead to either exaggeration or 
underestimation of the effect (182). Recall bias is one example of differential 
misclassification. Recall bias is likely to happen in any study that relies on subject 
memory (182). An advantage with using the HADS (study I–III) and ADI (paper I and 
II) parameters from the HUNT questionnaires is that the demands on subject memory is 
low, as the respondents were instructed to report how they had felt during the last week 
for HADS (185), and in the present moment for three of the ADI-items and during the 
last month for the item nervousness (172). In order to assess association of repeated 
anxiety or depression symptoms with CVD risk we utilized the dataset from the 
previous HUNT wave for those who had participated both times. Another option for 
paper I and II would have been to use the 5-items assessing lifetime depressive episode 
which was included at baseline in HUNT2 (but not in HUNT3): ”During your life, have 
there been periods of 2 consecutive weeks or more when you: 1) felt sad, depressed or 
down; 2) had appetite problems or ate too little, 3) felt weak (adynamic) or lacked 
energy; 4) really reproached yourself or felt worthless or 5) had problems concentrating 
or had difficulty making decisions”. However, although these items represent DSM-IV 
criteria of major depression, this could have introduced recall bias and we therefore 
chose to use data from HUNT1 to avoid this. 
Non-differential misclassification occurs if the misclassification of exposure is 
unrelated to the outcome (or vice versa) and typically leads to an underestimation of the 
effect, i.e. closer to the null than the true effect (182). Using self-report instruments 
people often tend to present themselves in a favourable light, e.g. people tend to under-
report smoking and alcohol use, while exercise frequency often is over-reported (186). 
In contrast, some studies argue that self-report provide a feeling of anonymity which 
increase reliable data of anxiety and depression symptoms (186). In paper I and II which 
encompassed a large proportion of the normal population in Nord-Trøndelag, the 
prevalence for HADS depression and anxiety symptoms defined as the highest cut-off 
(≥11) were comparable to the estimates from a psychiatric interview approach in the 
general European population (187).  
For screening, assessment of severity and decision making purposes it is 
common, and often necessary, to categorize continuous variables in order to help 
identify which patients are in need for follow-up for their anxiety and depression 
symptoms (170, 188). This was also the main approach in this thesis. In general the 
downside of categorizing continuous variables is high, including loss of information 
with reduced power to detect a relation between the variable and an outcome measure 
(182). However, in paper II the use of the continuous HADS scale supported the 
findings from the categorical approach, and the findings from paper I have recently 
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been supported by another study from HUNT using the continuous HADS-D scale in 
assessing association with AMI risk (189). 
There is also a possibility for misclassification in the identification and 
ascertainment of AMI (paper I), HF (paper II) and interpretation of the 
echocardiography recordings (study III). However, the reproducibility of the 
echocardiographic LV measures was high with an inter-observer mean error between 4–
8% and an intra-observer mean error between 2–5% (56). Also, the overall quality of 
the diagnosis of AMI and HF at the time of hospital discharge is high in Nordic 
countries and in the mid-Norway region (176, 178, 190). The quality of the HF 
registries appears slightly less precise than the AMI registries because there is no 
unequivocal definition for HF. For this reason we used only the primary diagnosis for 
HF as recommended (178). Nevertheless, the choice of including only primary 
diagnosis of HF leads to a possible underestimation of the true incidence. However, our 
main purpose was to ensure the most valid diagnosis, not give precise estimates on HF 
incidence in the general population. As the HF diagnosis had approximately 100% 
specificity, low sensitivity does not lead to bias of the risk ratios, just decreasing the 
precision (182). In short, to include only primary diagnosis of HF may decrease power, 
yet preserves validity. Additionally, sensitivity analysis including endpoints from 
hospital registries only (paper I and II) showed similar effects as the main analysis, and 
therefore it seems unlikely that the lower reliability of the National Cause of Death 
registries could have explained the effects. 
Confounding arises when the exposure and outcome share a common cause 
(191). Confounding can lead to overestimation, underestimation and even cause an 
association in the opposite direction of the true effect (182). One way to increase the 
knowledge about confounding is to visualize the hypothetical relations among variables 
of interest in directed acyclic graphs (DAGS) (191). Age and sex are examples of 
variables that based on our subject matter knowledge are confounders in studies I–III; 
both CVD and symptoms of depression and anxiety increase with age and differs by 
sex. Both variables (age and sex) must be directed to depression and the outcome (AMI 
in paper I, HF in paper II, subclinical LV dysfunction in study III). A statistical model 
that only includes such verified confounders are the best for analysing causality (182). 
When one adjusts or condition on such confounders in the statistical model, 
confounding caused by those variables is removed from the estimates (191). 
In study III we included average heart rate during echocardiography as a third 
covariate in model 1 because the interpretation of the echocardiographic recordings is 
pulse dependent. However, since increased heart rate during clinical procedures such as 
echocardiography may be an exaggerated physiological response associated with 
depression and anxiety symptoms (192), heart rate could be a mediator between the 
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exposure and outcome. This could have led to an underestimation of the effect of 
anxiety and depression symptoms on subclinical heart dysfunction. 
Residual confounding in observational studies can not be ruled out due to 
missing information on factors that could have a confounding effect (193). Even though 
our adjustments were extensive compared to most prior research in the same area (3), 
we lacked information on important potential confounders such as dietary patterns, 
neurohormonal stress levels and inflammatory activity. These factors are all associated 
with both the exposure (115, 137, 194) and the outcome (12, 17, 195). However, it is 
not clear whether these factors represents confounders, mediators or are part of a loop-
feedback mechanism in the observed associations (115, 140). In order to largely affect 
the gained estimates the unmeasured confounders must also be unrelated to the other 
factors that were already included in the analyses (182). However, inflammation is 
associated with smoking, BMI, lipids and alcohol (115), and diet is associated with 
BMI, lipids and hypertension (196). Thus, theoretically these variables would not 
largely influence the estimates. 
Among the most overlooked confounders between anxiety and depression 
symptoms with CVD risk are comorbid physical disorders (85, 86). Depressive 
symptoms are highly correlated with the overall disease burden, and several common 
chronic disorders are also risk factors for AMI, HF (193) and subclinical LV 
dysfunction (51). In paper I and II we handled this problem with performing sensitivity 
analysis where those with comorbid physical disease were excluded. In study III, the 
inclusion criteria for the echocardiography study excluded many comorbid conditions, 
see Figure 5. In Figure 5 the grey arrows indicate the inclusion criteria and the random 
selection for the echocardiography study and blue arrows represent the sources of data 
extraction for one and sum of two reports of anxiety and depression symptoms. 
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Figure 5: Sources of selection for the echocardiography study and data extraction for 
one and two reports of anxiety and depression symptoms. 
 
 
External validity  
External validity refers to generalizability, that is to what extent findings apply to other 
populations (182). Differences in prevalence of anxiety and depression symptoms, CVD 
risk factors and CVD rates may vary between study settings, countries and cultures. 
Moreover, the somewhat low participant rate (52%) and the health related reasons for 
non-participating in the oldest (>70) group (166, 167), makes it necessary to be cautious 
about inference from our results to the elderly population. Nevertheless, it is little 
reason to believe that the effect of depression and anxiety on CVD would be radically 
different in other populations. 
 
5.2 Comparison with previous studies.  
Although anxiety and depression symptoms tend to overlap, these conditions 
have to date mostly been investigated separately in terms of risk of AMI, HF and 
subclinical LV dysfunction. A meta-analysis of 23 prospective studies of risk associated 
with a wide range of anxiety measures for future AMI, found a pooled relative risk 1.26 
(95% 1.15–1.38) (4), which is close to our estimates. To the best of our knowledge no 
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studies exist on the association between anxiety symptoms and subclinical LV 
dysfunction, and we found only one prospective study of anxiety disorders and HF 
(197): a large (n=236,079) study of American war veterans, where a HR 1.19 (95% CI 
1.10–1.28) of associated with anxiety disorders was found (197). This point estimate is 
also comparable to the 1.17 (95% CI 0.90–1.51) risk of future HF found in participants 
with a score ≥ 11 on the HADS-Anxiety scale in our study.  
Also for depression, the majority of studies is undertaken on risk for future AMI, 
whilst we found only five studies for the prospective risk associated with HF (155-157, 
162, 163) and one cross-sectional study (13) on the association with subclinical LV 
dysfunction. For depression and risk of future AMI, a meta-analysis including 54 
prospective studies reported a pooled effect of 1.95 (95% CI 1.51–2.51) on fatal and 
non-fatal AMI (3), which is considerably higher than our estimates. Some prospective 
studies have also found a lack of effect between depression and AMI and HF (3, 157, 
162). Studies using self-report instruments have generally found smaller effects than 
studies relying on clinical diagnosis or psychiatric interviews (3), which might indicate 
a dose-response effect of anxiety and depression symptoms with risk for CVD. People 
with present psychiatric disorders, e.g. people with major depressive disorder generally 
score higher on self-rating scales compared to those who do not fill the diagnostic 
criteria. However, defining optimal cut-offs for identifying depressive disorders with 
high specificity is challenging (170, 198). Thus, some studies using self-report might 
have failed to detect a relation due to sub-optimal cut offs for their exposure. This dose-
response effect, i.e. the higher levels of anxiety and depression levels the higher CVD 
risk, is confirmed in studies of future AMI and HF risk, and in the cross-sectional 
association of subclinical LV dysfunction (8, 13, 155, 189, 199, 200).  
Unfavourable socioeconomic and behavioural lifestyles may be a link between 
depression symptoms and increased CVD risk. These traditional cardiovascular risk 
factors were inadequately controlled for in most previous studies and it is still not clear 
to which extent these factors explain the observed association between depression 
symptoms and CVD (3). Depression, but not as much anxiety symptoms, is often 
strongly associated with traditional risk factors for AMI, HF and subclinical LV 
dysfunction, such as lower educational level, physical inactivity, unhealthy diet, obesity, 
smoking, medical adherence and poorer lifestyle (58, 115, 140, 201, 202). Some of 
these behaviours associated with depressive symptoms are factors that negatively 
influence the cardiovascular health (12, 14). In our studies of risk for AMI (paper I) and 
HF (paper II), people in the most severe symptom category of anxiety and depression 
symptoms both had a more unfavourable socioeconomic and cardiovascular risk profile. 
However, even if cardiovascular risk factors explained some of the risk associated with 
anxiety symptoms for AMI and all of the risk for HF, they did not explain the risk 
associated with depression symptoms for AMI and HF. In addition, the above 
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mentioned unhealthy behaviours are suggested to be sources of an inflammatory process 
with release of proinflammatory cytokines that can cause depression (115, 203), and the 
inflammatory process reciprocally are part of the pathophysiological processes that 
cause HF, AMI and subclinical LV dysfunction (52, 140, 161, 204, 205). Unfortunately, 
we did not have data on inflammation or proinflammatory cytokines on all participants, 
so we were unable to test if this was a potential confounder in the observed associations.  
The risk associated with number of episodes of anxiety and depression 
symptoms is another dose-response issue, and several studies report that repeated 
episodes contribute to a higher risk for AMI than single episodes (8, 150, 152, 206, 
207). To best of our knowledge no study was found for assessing risk associated 
repeated anxiety and depression symptoms with future risk for HF or the presence of 
subclinical LV dysfunction. People who experience recurrent episodes of anxiety and 
depression might be exposed to a prolonged biological stress response, which in turn 
lead to increased CVD risk (195). However, as we did not have data on biological stress 
markers, we were not able to test if this could have been confounders for the observed 
associations. One can also hypothesize that a single measurement could reflect a normal 
reaction to stressful events, whilst multiple episodes may better capture anxiety and 
depressive disorders (208), such as bipolar disorders, known for poorer adherence with 
lifestyle and medical advice (209). In our studies repeated MSAD constituted a higher 
risk of AMI and HF. In study III, repeated high levels of depression symptoms was 
linearly associated with lower LV function among participants free from diabetes, 
hypertension and CVD. However, the increased associated with MSAD for AMI (paper 
I) was partially explained by comorbid physical disease and with previous AMI for HF 
(paper II). 
Our sensitivity analysis suggested a higher risk in the first five years of follow-
up regarding depression symptoms with risk for AMI (paper I) but not for HF (paper II) 
in those with depression symptoms at baseline. This might, for AMI; reflect reverse 
causation, which might be harder to detect for HF since the outcome is manifesting in 
average 5.9 years later than the AMI diagnosis. The possibility that both depressive 
symptoms and subsequent CVD are caused by subclinical pathological processes, e.g. 
atherosclerosis in the case of AMI, is among the greatest challenges on the prospective 
association between depression and CVD (85, 86). One possible pathway is the 
depressogenic actions of the increased inflammatory activity (210, 211). Inflammation 
is known to be one of the initiating pathophysiological processes behind arteriosclerosis 
(24), a driver in the LV myocardial remodelling (40) and neuroimaging and 
neuropathology studies has also found that depression can arise from a cerebrovascular 
origin (203).  
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6 Conclusion and future perspectives 
The results of this thesis contribute to the understanding of the risk associated 
with anxiety and depression symptoms for development of future CVD. HADS-Anxiety 
symptoms were only a moderate risk factor for AMI and not for HF or LV dysfunction. 
HADS-Depression symptoms were a moderate risk factor for future AMI (paper I) and 
HF (II), and the increased risk was not explained by traditional cardiovascular risk 
factors.  
Repeated HADS-Depression symptoms, but not repeated HADS-Anxiety 
symptoms, were associated with subclinical LV diastolic dysfunction at baseline (study 
III). Repeated episodes of MSAD were risk factors for AMI (paper I) and HF (paper II). 
We had some indications that the increased risk with MSAD was explained by 
coexisting chronic disease (paper I) and by previous AMI (paper II).  
Sensitivity analysis indicated that the observed risk associated with depression 
symptoms could be explained by reverse causation for future AMI (paper I) but not HF 
(paper II). It might be harder to detect reverse causality with increased HF risk since the 
outcome is manifesting in average 5.9 years later than the AMI diagnosis.  
Strategies for screening, early prevention, and improved treatment of 
depressive and anxiety symptoms might have the potential to reduce development of 
CVD, and should therefore be carried out both in primary care settings and in specialist 
services. Also, better treatment of anxiety and depression could contribute to increased 
adherence to medical and behavioural advice in persons at risk of CVD or with 
established CVD.  
Finally, future research should assess the unexplained pathophysiological links, 
such as unhealthy dietary patterns, use of psychotropic drugs, neurohormonal stress, 
proinflammatory cytokines, and shared genetic disposition, which could explain the 
underpinning mechanisms linking depression symptoms and CVD.  
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Aims The nature of the association of depression and anxiety with risk for acute myocardial infarction (AMI) remains unclear.
Weaimed to study the prospective associationof single and recurrent self-reported symptomsof anxiety and depression
with a risk of AMI in a large Norwegian population based cohort.
Methods
and results
In the second wave of the Nord-Trøndelag Health Study (HUNT2, 1995–97) baseline data on anxiety and depression
symptoms, sociodemographic variables, health status including cardiovascular risk factors and common chronic disor-
ders were registered for 57 953 adult men and women free of cardiovascular disease. The cohort was followed up
during a mean (SD) 11.4 (2.9) years for a ﬁrst AMI from baseline through 2008. A total of 2111 incident AMIs occurred,
either identiﬁed at hospitals or by theNational CauseofDeathRegistry. Themulti-adjusted hazard ratioswere 1.31 (95%
CI 1.03–1.66) for symptoms of depression and 1.25 (CI 0.99–1.57) for anxiety. Two episodes of mixed symptoms of
anxiety and depression (MSAD), reported 10 years apart, increased the risk for AMI by 52% (11–108%). After exclusion
of the ﬁrst 5 years of follow-up, the association of depression symptoms with AMI risk was attenuated. Relative risk for
AMI with anxiety symptoms and MSAD weakened when participants with chronic disorders were excluded.
Conclusion Self-reported symptoms of depression and anxiety, especially if recurrent, were moderately associated with the risk of
incidentAMI.Wehad some indications that these associationsmight partly reﬂect reverse causationorconfounding from
common chronic diseases.
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Introduction
Depression and anxiety, both highly prevalent conditions in the
general population, are associated with elevated risk for acute myo-
cardial infarction (AMI).1–7 However, the nature of this association
remains controversial.
One of the greatest challenges in the research on the prospective
association of anxiety and depression with AMI is that atheroscler-
osis, one of the main underlying pathophysiological mechanisms of
AMI, is known todevelop during decades before theﬁrst clinical symp-
toms.8However, almost all studies of depression includedmiddle aged
or older adults, often with a short follow-up time.9 Thus, individuals
free from clinical heart disease in the aforementioned prospective
studies may not be free from atherosclerosis, which may facilitate de-
pressive symptoms even before generating ischaemia.8,10
Furthermore, inmost previous reports, thewell-knowncardiovas-
cular risk factors were inadequately controlled for, and it is not clear
to what extent these factors explain the observed association
betweendepression andAMI.1,9,11Among themost overlookedcon-
founders are comorbid physical disorders.12 Depressive symptoms
are highly correlated with the overall disease burden, and several
common chronic disorders are also risk factors for AMI. Moreover,
depression is known to have an episodic nature,13 yet in the greatma-
jority of previous studies, depression was assessed only once. Some
studies, however, suggest that recurrent depression has considerably
stronger association with AMI than single depressive episodes.14
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Further, anxiety and depression are often considered separate
psychopathological conditions, yet they share common symptoms
and often overlap.15 Still, relatively little data are available on the
prospective association between anxiety and risk for cardiovascular
disorders (CAD), and similar methodological concerns as those
presented for depression apply to these studies as well.16 Therefore,
the aim of this study was to investigate the prospective association of
single and recurrent self-reported symptoms of anxiety and depres-
sionwith the riskofAMI controlled forpotential confounders, includ-
ing comorbidities in a large population-based cohort.
Methods
Study population and setting
All adult citizens inNord-TrøndelagCounty,Norway, received apostal in-
vitation to participate in the second wave of the Nord-Trøndelag Health
Study (HUNT 2, 1995–97, http://www.ntnu.edu/hunt, last accessed 28
July 2013). In total, 94 187 individuals were invited and 65 215 (69%) par-
ticipated in the HUNT 2 study. The participants ﬁlled in questionnaires
(http://www.ntnu.edu/hunt/data/que, last accessed 28 July 2013) and
attended a baseline clinical examination. Details about the study have
been published elsewhere.17,18 Of the participants in HUNT 2, 47 316
also attended the ﬁrst wave of the HUNT Study (HUNT 1, 1984–86).19
This study was approved by the regional ethics committee for re-
search, by the National Directorate of Health, the Norwegian Data In-
spectorate, and the HUNT data access committee. All participants
gave written consent.
Exposure: depression and anxiety symptoms
The HUNT self-report questionnaire included a Norwegian version of
the Hospital Anxiety and Depression Scale (HADS),20 which assesses
core psychological symptoms of anxiety (HADS-A) and depression
(HADS-D) during the last week. The seven anxiety questions mirror
symptoms of worry and tension, while the seven depression items
mirror mainly symptoms of anhedonia and loss of interest. All questions
have a 4-point Likert scale response option from 0 (no symptom) to 3
points (highest symptom level). The HADS has shown good psychomet-
ric properties across various patient samples and settings.21
In total, 62 685 (96.1%) of the HUNT 2 participants had a valid HADS
response, deﬁned as response on 5 or more items on one subscale.
Missing response among thosewho ﬁlled in ﬁve or six itemswere replaced
basedon the sumof completed itemsmultiplied by7/5 or6/5, respectively.
Both subscales range from 0 (no symptoms) to 21 points.
We categorized the participants according to their HADS-D and
HADS-A scores, respectively, as having no symptoms of depression or
anxiety (score, 8), having mild to moderate symptoms (score 8–10),
and having severe symptoms (score ≥ 11).22 A combined total score
(HADS-T) for assessing the impact of mixed symptoms of anxiety/de-
pression (MSAD) was calculated by summing up valid HADS-A and
HADS-D scores. We categorized the participants into three groups:
no MSAD (score, 15), mild to moderate MSAD (score between 15
and 18), and severe MSAD (score ≥ 19).21
InHUNT1(1984–86), theAnxietyandDepression Index (ADI-4)was
included. ADI-4 is an acceptable indicator for MSAD (sensitivity 0.51,
speciﬁcity 0.93) and showed a high correlation (0.83) with the HADS-T
score.23 ADI has been used as a crude baseline measure of MSAD in
HUNT 1.23 ADI consists of four questions, two tapping into general
anxiety and two into depression. Two of the questions have four re-
sponse categories: nervousness ranging from never (1) to almost all the
time (4) and calmness which range from almost all the time (1) to
never (4). The two other questions had seven response categories;
mood, ranging from very downhearted (7) to very happy (1) and vitality
ranging from very strong and ﬁt (1) to very tired and worn out (7).
In total, 32 963 of the participants in the present study had validMSAD
scores both in HUNT 1 (ADI-4) and HUNT 2 (HADS-T). A variable to
indicate the combined burden of MSAD in HUNT 1 and HUNT 2 was
created in categories of never, one, and two episodes. MSAD in HUNT
2was deﬁned as cut off≥19 on theHADS-T scale.We then deﬁned pre-
vious episode of MSAD in HUNT 1 by scoring in the upper quartile on
ADI, cut-off at ≥14 points. ‘Never MSAD’ was as deﬁned as a scoring
,14 on ADI in HUNT 1 and ,19 on HADS in HUNT 2, ‘MSAD once’
was deﬁned as scoring above cut-off in one of the studies, while ‘MSAD
twice’ included those scoring above cut-off in both studies.
Follow-up and outcome ascertainment
A total of 4734 participants were excluded at baseline because they
reported a history of previous myocardial infarction (n ¼ 1944), angina
pectoris (n ¼ 2978), or stroke (n ¼ 1120). The remaining 57 953 partici-
pants were included in this study, and Figure 1 summarizes the recruit-
ment of the participants.
Participantswere followed-up for aﬁrstAMI fromenrolment inHUNT
2 study until 31th ofDecember 2008, either identiﬁed at the two hospitals
in Nord-Trøndelag County or by the National Cause of Death Registry.24
Acutemyocardial infarctionwas diagnosed according to the European
Society of Cardiology/AmericanCollege of Cardiology consensus guide-
lines.5 Criteria for AMI included: (i) speciﬁc clinical symptoms according
to case history information, (ii) changes in blood levels of cardiac
enzymes, and (iii) speciﬁed ECG changes. Fatal AMI incidents that
never reached the emergency units at the hospitals were identiﬁed in
the National Cause of Death Registry by the International Classiﬁcation
of Diseases codes (code no. 410 in the 9th revision and codes I21 and I22
in the 10th revision). Duringmean (SD) 11.4 (2.9) years of follow-up, 231
participants who left the county, and 6409 participants who died from
other causes than AMI, were censored at the time of event (emigration
or death) in the statistical analyses (see Figure 1 , ﬂow chart).
Covariates
Demographic factors
Cohabitation status was dichotomized as living with a partner or alone.
Education was categorized as low (≤ 9 years), medium (between 10
and 12 years), or high (over 12 years).
Life style factors
Smoking habits were self-reported andwere categorized as current, pre-
vious, or never smoking. Physical activity was deﬁned as light if it did not
involve sweating or feeling of breathlessness, while hard physical activity
was deﬁned by sweating or breathlessness. The participants were cate-
gorized as inactive (less than 1 h of hard activity and less than 3 h of
light physical activity per week), moderate active if they reported 1–
3 h of hard activity or .3 h of light activity per week, and as physically
active if they reported .3 h of hard physical activity per week.
Chronic somatic disorders
Participants self-reported if they had (or had ever had) cancer, asthma,
diabetes mellitus, other endocrine disorders (hypothyreosis, hyperthyr-
eosis, goitre, and thyroiditis), musculoskeletal disorders (osteoporosis,
ﬁbromyalgia, and arthrosis/arthritis), autoimmune disease (Bechterew
disease, rheumatoid arthritis), epilepsy, or other chronic disorders (re-
plying yes to the question ‘do you have or ever had any other chronic
disease’ and no to the questions regarding previous speciﬁed diagnosis
of chronic disease).
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Clinical examination
Blood pressure, heart rate, weight, height, waist, and hip circumference
were measured by specially trained nurses after a standardised protocol.
Heart rate, and systolic and diastolic blood pressureweremeasured after
the participant had been seated for at least 2minwith the cuff on, and the
size of the cuff was adjusted for arm circumference.17 All blood pressure
and heart rate recordings were performed using aDinamap 845XT (Cri-
ticon) basedonoscillometry and involved automatically three recordings
at 1 min intervals. The ﬁrst heart rate recording was in average 2 bpm
lower than the second and third measurement and was thus used in
order to mirror resting heart rate. For blood pressure, the value
decreased for each recording, thus we used the average of the second
and third measurements in our analysis. Height was measured without
shoes to the nearest 1.0 cm and weight with light clothing to the
nearest 0.5 kg.17 Body mass index (BMI) was computed as weight (in
kg) divided by the squared value of height (in metres).
Blood sampling and laboratory measurements
A non-fasting whole blood sample was drawn from each participant, and
the time between last meal and the venepuncture was recorded. Serum
was separated by centrifugation at the screening site and immediately
placed in a refrigerator (48C). The samples were sent (same day or fol-
lowing Monday for samples drawn on Friday) for analyses at the central
laboratory at Levanger Hospital, Norway, where they used a Hitachi
911 Autoanalyzer, applying reagents from Boehringer Mannheim.
Serum total cholesterol was measured by an enzymatic colorimetric
cholesterol esterase method. The day-to-day coefﬁcient of variation
for total cholesterol was 1.3–1.9%.17
Statistical analysis
Comparisons of continuous variables among those who developed AMI
during follow-up and those who did not were made by two-sided t-test,
and thex2 test was used to compare categorical data.We usedCox pro-
portional hazard models to examine the association of depression and
anxiety symptoms and subsequent risk for AMI. We calculated hazard
ratios (HRs) and 95% conﬁdence intervals (CIs). For test of trends, we
assigned a numeric value of 0 to 2 to the HADS categories, with 0
having no, 1 having moderate, and 2 having severe anxiety or depression
symptoms, treating the categories as a continuous variable. In a separate
analysis, we calculated the risk for AMI associated with the presence of
MSAD in HUNT 1 and HUNT 2 when those without symptoms of
MSAD in both of the surveys constituted the reference group.
Figure 1 Flow chart for the participants.
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Weadjusted all ourmodels for sex and age as a continuous variable. In
the second adjustment model, we added education and marital status as
potentially confounding factors in ourmodels. Established cardiovascular
risk factors such as resting heart rate, high blood pressure, low physical
activity, high BMI, smoking, dyslipidemia, and diabetes mellitus may act
both as confounding and mediating factors for the association of depres-
sion and anxiety with the AMI risk. We therefore analysed the data both
with and without the factors included in the analyses. We conducted
several stratiﬁed analyses to assess whether the association of anxiety
and depression and the risk for AMI could be modiﬁed by other factors.
We investigated the potential effect modiﬁcation by sex, age (dichot-
omized at age 50 and age 65), BMI (dichotomized at ≥35 kg/m2), total
cholesterol (dichotomized at 6.5 mmol/L), education (dichotomized at
12 years), blood pressure (systolic blood pressure dichotomized at
.140 mm Hg, diastolic at .90 mm Hg), and smoking status (current
vs. no current smoking). We also formally tested the homogeneity of
stratum-speciﬁc relative risks. For these tests of interaction, we used
the trend variable as deﬁned above.
We present event-free survival curves using the Kaplan–Meiermethod
according to symptom categories.
We performed several sensitivity analyses to assess the robustness
of our ﬁndings. First, we excluded participants with cancer, asthma, dia-
betes mellitus, other endocrine disorders, musculoskeletal disorders,
and autoimmune diseases or other reported chronic disorders. We
also restricted the analysis to AMI cases that were conﬁrmed at the hos-
pital, thus cases whose AMI diagnosis were based on death certiﬁcates
alone were excluded from the analyses. Finally, in order to address the
possibility of reverse causation as an explanation for possible associations,
we excluded the ﬁrst 5 years of follow-up and repeated the analyses. All
sensitivity analyses were run with adjustments for socioeconomic status
and traditional cardiovascular risk factors (Model 3).
We tested the proportionality of hazard using log–log curves and
formal tests of interaction with time or log-time. There was no evidence
against the proportionality assumption (all P . 0.10).
Statistical analyses were performed in Stata IC/12.1 for windows (&
Stata Corp LP).
Results
Characteristics of the study population, by AMI status, are shown in
Table 1. Among the 59 953 participants, 2111 (3.5%) had a ﬁrst AMI
during follow-up. Of these, 1632 cases were diagnosed at a hospital
and479caseswere registeredby theNationalCauseofDeathRegistry
alone.
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Table 1 Baseline characteristics of participants in the total population and according toAMI vs. noAMI during follow-up
Variable No. of subjects Total population AMI during follow-up No AMI during follow-up P-value
Total % (n) 57 953 % 3.6 (2111) 96.7 (55 854)
Variables, % (n)
Male sex 26 551 45.8 62.5 (1312) 45.2 (25 239) ,0.0001
Diabetes mellitus 1292 2.2 8.3 (176) 2.0 (1 116) ,0.0001
Smoking ,0.0001
Never 26 669 46.2 34.0 (714) 46.6 (25 955)
Former 13 748 23.8 28.0 (608) 23.6 (13 140)
Current 17 334 30.0 36.0 (775) 29.8 (16 569)
Physical activity ,0.0001
Inactive 20 333 38.1 46.9 (796) 37.8 (19 537)
Moderately active 27 574 51.7 46.5 (788) 51.9 (26 786)
Physically active 5434 10.2 6.6 (112) 10.3 (5322)
Living alone 23 009 39.8 35.9 (757) 39.9 (22 252) ,0.0001
Education ,0.0001
≤9 years 18 930 33.7 63.2 (1468) 32.8 (17 763)
10–12 years 25 311 45.1 27.3 (632) 45.7 (24 765)
.12 years 11 857 21.1 9.0 (133) 21.5 (11 661)
Mean (SD)
Age, years 57 953 47.7 (16.3) 64.9 (12.7) 47.0 (16.0) ,0.0001
Body mass index, kg/m2 57 498 26.2 (4.1) 27.4 (4.0) 26.2 (4.1) ,0.0001
Systolic blood pressure, mmHg 57 586 123.5 (21.1) 153.9 (23.5) 135.8 (20.7) ,0.0001
Diastolic blood pressure, mmHg 57 586 79.9 (12.0) 87.1 (12.7) 79.7 (11.9) ,0.0001
Resting heart rate, bpm 57 673 71.6 (13.0) 73.4 (13.5) 71.6 (13.0) ,0.0001
Total cholesterol, mmol/L 57 644 5.8 (1.2) 6.7 (1.2) 5.8 (1.2) ,0.0001
HADS—depression score 57 819 3.4 (3.0) 4.1 (3.0) 3.4 (3.0) ,0.0001
HADS—anxiety score 57 023 4.2 (3.3) 3.9 (3.4) 4.3 (3.3) ,0.0001
HADS—total score 56 889 7.6 (5.6) 8.7 (5.8) 8.6 (5.4) 0.3555
ADI score (HUNT 1) 32 963 13.5 (1.2) 13.6 (1.3) 13.5 (1.2) 0.0036
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Using the highest cut off (≥11), the prevalence rates of HADS-
deﬁned anxiety and depression were 5.2 and 3.0, respectively.
These estimates were comparable with the corresponding values
(6.4 and 4.2%) found in the general European population.25
Inourstudy,womenreportedhigher symptomlevelsof anxietyand
MSAD, while depression symptom levels were the same in both
genders.
A total of 2111 participants had a ﬁrst AMI during a mean (SD)
follow-up of 11.4 (2.9) years. The prevalence of current smoking, dia-
betes, physical inactivity, and low education was higher among those
who developed AMI during follow-up.
Table 2 presents the HRs for AMI in relation to symptoms
of anxiety, depression, and MSAD. Risk for AMI was moderately
elevated for participants reporting symptoms of depression,
anxiety, and MSAD. The point estimates were fairly robust in multi-
variable models for socioeconomic and cardiovascular risk factors.
Additional adjustment for resting heart rate in model 3 did not
alter these results considerably (data not shown). Symptoms of
anxiety were associated with higher risks for non-fatal AMI (HR 1.33,
95% CI 1.03–1.71) than for fatal AMI (HR 0.93, 95% CI 0.70–1.24),
and this pattern was similar regarding symptoms of depression and
MSAD (data not shown).
Figures 2–5 show Kaplan–Meier curves for event-free survival
according to symptom categories and number of subjects at risk for
each 2.5 years of follow-up.
Table 3 displays the HRs for AMI according to the presence of
MSAD combining data from HUNT 1 and 2. In the study population,
48.4% (n ¼ 15 657) reported no episodes of MSAD, 48.9% (n ¼
15 770) reported one MSAD episode, and 2.7% (n ¼ 884) experi-
enced two MSAD episodes. There was a trend towards higher HRs
in those with two episodes of MSAD compared with those who did
not report MSAD at HUNT 1 or HUNT 2 and HRs were 30%
higher than for those reporting MSAD only in HUNT 2.
Sensitivity analyses
Table 4 presents themultivariable adjustedHRs for AMI in relation to
depression, anxiety, and MSAD in different sensitivity analyses.
There were 1582 AMI cases among 49 330 participants that com-
pleted the questionnaire on common chronic somatic disorders. Of
these, 13 515 persons (27.4%) reported to have at least one chronic
disease. The frequency of chronic disorders was: diabetes mellitus
n ¼ 902, other endocrine disorders n ¼ 1998, autoimmune diseases
n ¼ 1330, muscle/skeletal disorders n ¼ 4184, asthma n ¼ 3898,
cancer n ¼ 1323, epilepsy n ¼ 652, and ‘other chronic disorders’
n ¼ 1793. After exclusion of common chronic disorders, the effect
sizes were generally attenuated (Table 4). No single group of chronic
disorders appeared to be responsible for this effect.
When we restricted follow-up to AMI cases that were conﬁrmed
in hospital (1632) events, we obtained similar or even higher hazard
ratios for anxiety, depression, and MSAD than in the main analyses.
After theﬁfth yearof follow-up,weobserved1443AMIevents. Ex-
clusion of the ﬁrst 5 years substantially weakened the observed asso-
ciation between depression and AMI risk. Risk for AMI associated
with anxiety symptoms and MSAD remained fairly stable (Table 4).
Discussion
In this large population-based cohort study, participants with symp-
toms of anxiety, depression and mixed symptoms (MSAD) had a
20–30% increased risk for ﬁrst AMI. Participants reporting two epi-
sodes ofMSAD, 10 years apart, had.50% increased risk for AMI. All
effects were robust to extensive adjustments for socioeconomic and
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Table 2 Hazard ratios (95% conﬁdence intervals) for AMI during follow up according to symptoms of depression
(HADS-D) and anxiety (HADS-A) and mixed anxiety/depression symptoms (MSADmeasured by HADS-T) in HUNT 2
(1995–97)
Variable Model 1 Model 2 Model 3
HADS-D Events/person-time 2096/656 582 1896/636 445 1561/590 365
0–7 Reference Reference Reference
8–10 1.08 (0.94–1.24) 1.03 (0.88–1.19) 0.91 (0.77–1.09)
≥11 1.32 (1.07–1.61) 1.25 (1.01–1.56) 1.31 (1.03–1.66)
P for trend 0.008 0.074 0.253
HADS-A Events/person-time 2012/648 777 1847/630 642 1533/586 848
0–7 Reference Reference Reference
8–10 1.02 (0.87–1.20) 1.00 (0.84–1.18) 0.91 (0.76–1.00)
≥11 1.30 (1.06–1.60) 1.30 (1.06–1.61) 1.25 (0.99–1.57)
P for trend 0.027 0.049 0.309
HADS-T Events/person-time 1997/647 414 1836/629 490 1528/586 132
0–12 Reference Reference Reference
15–19 1.02 (0.85–1.21) 1.00 (0.83–1.20) 0.87 (0.70–1.07)
≥19 1.26 (1.04–1.51) 1.24 (1.02–1.51) 1.22 (0.98–1.51)
P for trend 0.032 0.066 0.345
HR indicates hazard ratio; CI, conﬁdence interval; AMI, acute myocardial infarction.
Model 1: adjusted for calendar age and sex. Model 2: Model 1 + marital status, education.
Model 3: Model 2 + smoking, physical activity, body mass index, total cholesterol, diabetes mellitus, systolic blood pressure.
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traditional cardiovascular risk factors. For depression symptoms, the
effect was only evident the ﬁrst 5 years of follow-up, which raises a
possibility for a reverse causation. For anxiety symptoms and
MSAD, AMI risk attenuated with exclusion of participants with co-
existent chronic physical illnesses at baseline,which probably reﬂects
confounding.
Comparisons with previous studies
Although anxiety and depression symptoms tend to overlap, these
conditions have to date mostly been investigated separately in
terms of risk for AMI.10 A recent meta-analysis of 23 prospective
studies including a wide range of anxiety measures, found a pooled
effect-size associated with incident cardiac heart disease of 1.26
Figure 2 The Kaplan–Meier curve of incident acute myocardial infarction and subjects at risk during follow-up according to HADS-Depression
symptom categories.
Figure 3 The Kaplan–Meier curve of incident acute myocardial infarction and number of persons at risk during follow-up according to
HADS-Anxiety symptom categories.
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(95% 1.15–1.38).26 Only 22% of the anxiety studies included in the
meta-analysis consisted of both men and women.26 In our study,
the relative risks for AMI in relation to anxiety and depression symp-
tomswere similar in the two sexes and theoverall effectwas compar-
able to previous studies.26
For depression, another meta-analysis including 21 prospective
studies reported a pooled effect of 1.95 (95% CI 1.51–2.51) on
CAD death and AMI,9 considerably higher than the point estimates
found in our study.We can think of several explanations for this dis-
crepancy; ﬁrst, studies using self-report instruments have generally
Figure 4 The Kaplan–Meier curve of incident acute myocardial infarction and number of persons at risk during follow-up according to
HADS-Total symptom categories.
Figure 5 The Kaplan–Meier curve of incident acute myocardial infarction and number of persons at risk during follow-up according to mixed
anxiety and depression symptom categories in HUNT 1 and 2.
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found smaller effects than studies relying on clinical diagnosis or
psychiatric interviews.9 Second, adjustment for cardiovascular risk
factors andcomorbidphysical illness(es)was limited inmostprevious
studies. Third, largepopulation-based studies tended to report lower
point estimates than smaller studies probably due to publication
bias.9 Finally,we shall emphasize that previous studies useddiagnostic
interviews or self report instruments that included awide depressive
symptom spectrum, such as sleep problems, lack of energy and dis-
turbed appetite. These symptoms greatly overlap with symptoms
of common physical illnesses, including subclinical coronary artery
disease.13 As a result, the genuine contribution of core psychological
and cognitive symptoms of anxiety and depression to cardiovascular
morbidity has been uncertain. Importantly, the tool used in the
current study, i.e. HADS, was originally designed for detection of
anxiety and depression in patients with physical illness, and systemat-
ically excludes somatic symptoms which can mimic heart disease.22
Hence, our study is oneof the ﬁrst to link corepsychological and cog-
nitive symptomsof anxiety and depression to amoderately increased
AMI risk. Nevertheless, by using this approach, some participants
with predominantly somatic symptoms of depression might go un-
detected. As a consequence, we are likely to have underestimated,
rather than overestimated, the association between depression and
AMI in our study.
Most studies conﬁrm that comorbid anxiety and depression are
associated with more severe illness, worse outcome, and increased
mortality comparedwith single conditions.27 Thiswas not conﬁrmed
in our study, as we found no excess risk for AMI associated with
MSAD in HUNT 2.
Limited previous evidence suggested that information on anxiety
or depressive symptoms provided by repeated measures enable a
considerably better risk prediction when compared with the informa-
tion derived from a single measurement.1,3,28,29 Our study supports
these earlier ﬁndings and suggests that persistent or recurrent symp-
toms might be associated with increased cardiovascular risk. One
can hypothesize that a single measurement could reﬂect a normal re-
action to stressful events, while multiple episodes may better capture
anxiety and depressive disorders,30 such as bipolar disorders, known
for poorer adherence with lifestyle and medical advice.31
Our sensitivity analysis regarding depressive symptoms, but not
anxiety or mixed symptoms, indicate a higher risk for AMI in the
ﬁrst 5 years of follow-up. This might reﬂect a reverse causation.
The possibility that both depressive symptoms and subsequent
AMI are caused by subclinical manifestations of atherosclerosis is
among the greatest challenges for research on the prospective asso-
ciation betweendepression andAMI.12,13 Individuals free from clinic-
al heart disease included in prospective studies may not be free from
atherosclerosis, which is known to develop during decades before
ﬁrst symptoms.8,10 Thus, individuals free from clinical heart disease
included in prospective studiesmay not be free fromatherosclerosis.
Atherosclerosismay facilitate depressive symptoms evenbefore gen-
eratingcardiac ischaemiacreatinga spuriousassociationbetweendepres-
sion and atherosclerosis. One possible pathway is the depressogenic
actionsof the increased inﬂammatoryactivity.32,33Moreover, neuroi-
maging and neuropathology studies suggest that late onset depres-
sion often has a cerebrovascular origin.34 Cerebral atherosclerosis
may thus facilitate depressive symptoms even before coronary ath-
erosclerosis generates cardiac ischaemia.
Several epidemiological ﬁndings supported the reverse causality
hypothesis. Studies with a shorter follow-up generally show stronger
associationwithAMI.9 In the PRIME study, depressive symptomswere
associated with coronary heart disease only in the ﬁrst 5 years of
follow-up,35 a ﬁnding which is conﬁrmed in our study. There were
some studies with null ﬁndings which were conducted in young popu-
lations, where vascular depression and subclinical CAD are less likely.
In a study of healthy US army personnel 39–45 years of age,36 no cor-
relationwas foundbetweendepressionandsubclinical coronaryartery
disease identiﬁedbyelectron-beamcomputedtomography. Further, in
a large prospective cohort study ofmenwhowere 19–21 years old at
baseline, only anxiety but not depression was associated with future
CAD risk.37
While adjustment for established cardiovascular risk factors was
extensive in several studies regarding anxiety,26 many prospective
studies of depression and AMI risk failed to adjust even for well-
known cardiovascular risk factors such as smoking and physical activ-
ity.9 Furthermore, comorbid physical disorders are among the most
overlooked confounders in previous prospective studies of anxiety
ordepression and subsequent heart disease.12Depressive symptoms
are highly correlated with the overall disease burden, and several
common chronic disorders are risk factors for AMI.13 In the
present study, AMI risk in participants with symptoms of anxiety
and MSAD at baseline was attenuated considerably after excluding
all participants with comorbid chronic diseases from the analysis. In
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Table 3 The association between episodes of mixed symptoms of anxiety and depression (MSAD) in HUNT 1 and 2, and
risk of subsequent acute myocardial infarction
Number of episodes MSAD Model 1 Model 2 Model 3
Events/person years 1491/372 505 1368/361 051 1145/333 405
Never MSAD (n ¼ 15 657) Reference Reference Reference
MSAD once (n ¼ 15 770) 1.07 (0.97–1.19) 1.06 (0.96–1.19) 1.02 (0.99–1.14)
MSAD twice (n ¼ 884) 1.63 (1.24–2.19) 1.65 (1.24–2.20) 1.52 (1.11–2.08)
P for trend 0.009 0.016 0.184
Results presented as HR’s (95% CIs).
Model 1: adjusted for calendar age and sex.
Model 2: Model 1 + marital status, education.
Model 3: Model 2 + smoking, physical activity, body mass index, total cholesterol, diabetes mellitus+ systolic blood pressure.
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contrast, the excessAMI risk in thosewith depression symptoms and
recurrent MSAD was more robust throughout these analyses.
Strengths and limitations
Compared with prior studies, we had an ample statistical power
to address the prospective association between symptoms of de-
pression and anxiety, and the risk for AMI. The population-based
nature of the study, the high stability (less than 0.3% net migration/
year), and relatively high genetic and socioeconomic homogeneity
of the population17 along with reliable hospital and register informa-
tion covering the entire county, ensured close to complete follow-up
andminimized the possibility for themisclassiﬁcation of endpoints or
for a selection bias.24Moreover, in contrast tomanyprevious studies,
we could extensively control for potentially confounding factors.
Yet, the presentwork has some important limitations. Attendance
in HUNT 2 was generally high, but considerably lower in the age
group of 70 years and older.19 Further, we had no information on
treatment for depression. SSRIs, themost commonly usedmedication
for anxiety and depression, are known to reduce platelet adhesion38
and increase BMI39 and therefore are potential mediators for the
observed associations. However, in the present study, it was not pos-
sible to separate the effect of depression and its eventual treatment.
Conclusion
Our ﬁndings indicate that self-reported core psychological symp-
tomsof depression and anxiety, especially if recurrent, aremoderate-
ly associated with the AMI risk. We had some indication that these
associations might partly reﬂect reverse causation (depression) or
confounding from common chronic diseases (anxiety and mixed
anxiety and depression).
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Table 4 Risk for acute myocardial infarction associated with symptoms of anxiety and depression in sensitivity analyses
Exclusion of all
chronic
diseasesa
Restriction to
hospital veriﬁed
AMI
Exclusion of ﬁrst
5 years of
follow-up
HADS—depression
Events/ person
years
768/384 975 1228/51 442 1082/341 485
Cut off 8–10 0.95 (0.74–1.23) 0.94 (0.44–1.15) 0.96 (0.78–1.18)
Cut off ≥11 1.25 (0.81–1.91) 1.33 (1.02–1.75) 1.14 (0.83–1.57)
P for trend 0.632 0.203 0.673
HADS—anxiety
Events/person years 762/384 068 1209/586 848 1060/345 716
Cut off 8–10 1.08 (0.82–1.43) 0.97 (0.79–1.19) 0.87 (0.69–1.10)
Cut off ≥11 1.14 (0.74–1.75) 1.33 (1.03–1.71) 1.32 (1.00–1.73)
P for trend 0.439 0.099 0.321
HADS—total
Events/person years 761/383 732 1205/586 132 1057/339 216
Cut off 15–19 0.75 (0.53–1.05) 0.89 (0.70–1.31) 0.80 (0.61–1.05)
Cut off ≥19 1.07 (0.72–1.58) 1.27 (1.00–1.61) 1.23 (0.95–1.59)
P for trend 0.559 0.202 0.563
MSAD (HUNT 1 and 2)
Events/person years 587/204 678 908/333 405 787/27 215
One episodeMSAD 0.93 (0.79–1.09) 1.07 (0.93–1.22) 1.06 (0.92–1.23)
Two episodeMSAD 1.38 (0.79–2.40) 1.81 (1.29–2.52) 1.75 (1.21–2.53)
P for trend 0.688 0.022 0.053
MSAD, mixed symptoms of anxiety and depression.
aJoint effect of persons that reported asthma, diabetes, other endocrine disorders, musculoskeletal disorders, autoimmune diseases, epilepsy, cancer, and other chronic diseases.
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Aims Symptoms of anxiety and depression often co-exist with cardiovascular disease, yet little is known about the
prospective risk for heart failure (HF) in people with symptoms of depression and anxiety. We aimed to study these
prospective associations using self-reported symptoms of anxiety, depression, and mixed symptoms of anxiety and
depression (MSAD) in a large population sample.
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Methods
and results
In the second wave of the Nord-Trøndelag Health Study (HUNT 2, 1995–1997), Norway, baseline data on symptoms
of anxiety and depression, socio-demographic variables, health status including cardiovascular risk factors, and
common chronic somatic diseases were registered for 62 567 adults, men and women, free of known HF. The cohort
was followed for incident HF from baseline throughout 2008. A total of 1499 cases of HF occurred during a mean
follow-up of 11.3 years (SD= 2.9), identified either in hospital registers or by the National Cause of Death Registry.
There was no excess risk for future HF associated with symptoms of anxiety or MSAD at baseline. For depression,
the multi-adjusted hazard ratios for HF were 1.07 (0.87–1.30) for moderate symptoms and 1.41 (1.07–1.87) for
severe symptoms (P for trend 0.026). Established cardiovascular risk factors, acute myocardial infarction (AMI) prior
to baseline, and adjustment for incident AMI as a time-dependent covariate during follow-up had little influence on
the estimates.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Conclusion Symptoms of depression, but not symptoms of anxiety or MSAD, were associated with increased risk for HF in a
dose–response manner. The increased risk could not be fully explained by cardiovascular or socio-economic risk
factors, or by co-morbid AMI.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Keywords Depression • Anxiety • Prospective • Risk • Heart failure • Epidemiology
Introduction
Heart failure (HF) is often co-prevalent with symptoms of
depression1–8 and anxiety,3,9 and symptoms of depression have
been found to worsen the course and prognosis of established
HF.2,3,10
Ischaemic heart disease (IHD), like acute myocardial infarction
(AMI), is the main cause of HF in Europe and accounts for ∼60% of
HF.11 Other known precursors for HF are hypertension, diabetes,
cardiomyopathy, heart valve disease, and arrhythmias.12 In the
*Corresponding author. Department of Internal Medicine, Levanger Hospital, Kirkegata 2, 7600 Levanger, Norway. Tel: +47 410 44 326, Fax: +47 74 09 85 90, Email:
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.. development of HF, except HF initiated by AMI, the process of
myocardial remodelling often starts long before the onset of HF
symptoms.13 As HF is a major and increasingly important public
health problem, it is crucial to search for modifiable risk factors in
the aetiology of HF.14 It is plausible that symptoms of depression
and anxiety represent such modifiable risk factors as they have
been found to influence behavioural risk factors for HF, such as
obesity, reduced physical activity, alcohol abuse, and smoking.1,15
Furthermore, neurohormonal stress associated with symptoms of
depression and anxiety is known to regulate blood pressure, heart
© 2014 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and
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rate, proinflammatory cytokines, and circulating catecholamine
levels, which in turn promote HF.1,16
However, the prospective evidence supporting a link between
symptoms of depression and future HF arise from small studies of
elderly people, and the results are conflicting.4–8 To the best of our
knowledge, only one study, among US veterans, has investigated
the risk for future HF with symptoms of anxiety.17 We therefore
aimed to investigate the prospective association of self-reported
symptoms of anxiety and depression with risk for future HF in a
large population-based study, taking into account a large number
of established cardiovascular risk factors, previous and/or incident
AMI, several chronic somatic disorders, and previous symptoms of
anxiety and depression.
Methods
Study population and setting
All adult citizens in Nord-Trøndelag County, Norway, received a postal
invitation to participate in the second wave of the Nord-Trøndelag
Health Study (HUNT 2, 1995–1997, http://www.ntnu.edu/hunt). In
total, 94 187 individuals were invited, and 65 215 (69%) participated
in the HUNT 2 study. The participants attended a baseline clini-
cal examination and gave self-report on standardized questionnaires
(http://www.ntnu.edu/hunt/data/que). Details of the HUNT study have
been published elsewhere.18,19
The study was approved by the regional committee for medical and
health research ethics, by the National Directorate of Health, and by
the Norwegian Data Inspectorate.
Exposure: symptoms of anxiety
and depression
Participants self-reported symptoms of anxiety and depression
using a Norwegian version of the Hospital Anxiety and Depres-
sion Scale (HADS),20 which assesses core psychological symptoms
of anxiety (HADS-A) and depression (HADS-D) during the
previous week.
Seven depression questions mirror symptoms of anhedonia and loss
of interest, and seven anxiety questions mirror mostly symptoms of
worry and tension. We included all participants that responded to ≥5
items on one subscale (n= 62 693). For those who filled in only five or
six items on the HADS-A and -D subscales, missing scores were sub-
stituted based on the sum of completed items multiplied by 7/5 or 7/6,
respectively.21 All HADS questions have a 4-point Likert scale, ranging
from 0 (no symptom) to 3 (highest symptom level); thus the subscales
range from 0 points (no symptoms) to 21 points, which allows calcula-
tion of risk per unit increase in the HADS.21 In addition, recommended
cut-offs were used to categorize the participants as not depressed or
anxious (score <8), moderately depressed or anxious (score between
8 and 11), and severely depressed or anxious (score ≥11).22 Mixed
symptoms of anxiety and depression (MSAD) were calculated by
summing up valid HADS-A and HADS-D into HADS-total scores
(HADS-T) and categorized into no MSAD (score <15), moderate
MSAD (score between 15 and 18), and severe MSAD (score ≥19).23
Previous symptoms of MSAD were available for 36 418 participants
that also attended HUNT 1 (1984–1986) and filled in the 4-item
Anxiety and Depression Index (ADI-4). ADI-4 has a high correlation
(0.83) with the HADS-T score from HUNT 2 and is an acceptable ..
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.. indicator for MSAD (sensitivity 0.51, specificity 0.93).24 Two ADI
questions have a 4-point Likert scale: calmness, ranging from almost
all the time (1) to never (4); and nervousness, ranging from never (1)
to almost all the time (4). The last two ADI questions about mood and
vitality have a 7-point Likert scale ranging from very happy/strong and
fit (1) to very downhearted/tired and worn out (7). We categorized
symptoms of MSAD in HUNT 1 by scoring on the upper quartile
on ADI-4, i.e above a score of 14. Symptoms of MSAD in HUNT 2
were defined as a score ≥19 on the HADS-T subscale. A variable
to indicate the combined burden of MSAD in HUNT 1 and 2 was
created in categories of never (no symptoms of MSAD in HUNT 1
or 2), one (MSAD symptoms in one of the HUNT waves), and two
episodes (MSAD symptoms in both HUNT waves).
Outcome ascertainment
After baseline, the participants were followed up for a first incident
of HF until 31 December 2008, identified either by linkage with med-
ical records at the two hospitals in Nord-Trøndelag county or by the
National Cause of Death Registry.25 A total of 126 participants were
excluded because their medical records indicated HF before they par-
ticipated at baseline. Therefore, 62 567 people were included in the
analyses, as displayed in Figure 1. Heart failure was defined and diag-
nosed according to the current European Society of Cardiology (ESC)
Guidelines.26 The overall quality of the hospital discharge diagnosis of
HF is generally high in Nordic countries.27,28 In order to increase speci-
ficity, we only extracted primary diagnoses as recommended.27 Deaths
due to HF were extracted from the National Death Registry. We used
International Classification of Diseases (ICD) 9 code 428 and ICD
codes I50.0, I50.1, and I50.9 to identify HF.25 Having 100% specificity
and low—but non-differential—sensitivity leads to no bias of the risk
ratio. Even a slight decrease in specificity, even if non-differential, might
lead to a severe bias. Therefore, in brief, our decision to include only
primary diagnosis decreases our power, but preserved our validity.29
During an average of 11.3 years of follow-up, 8164 participants who
died of causes other than HF and 224 who left the county were
censored at time of death or emigration (see Figure 1).
Covariates
Demographic and lifestyle factors
Cohabitation status was dichotomized as living with a partner or alone.
Education was categorized as low (≤9 years), medium (between 10 and
12 years), or high (over 12 years).
Smoking habits were self-reported and were categorized as current,
previous, or never smoking. We categorized the participants according
to self-reported alcohol consumption as abstainers, very light drinkers
(0–1 drinks per day), light to moderate drinkers (1–2 drinks per day),
or moderate to heavy drinkers (>2 drinks per day). Physical activity
was reported as light or hard, defined respectively as activity excluding
or including sweating or feelings of breathlessness. The participants
were categorized as inactive (<1 h of strenuous activity and <3 h of
light physical activity per week), moderately active (1–3 h of strenuous
activity or >3 h of light activity per week), and as physically active (>3 h
of strenuous physical activity per week).
Common chronic somatic diseases
The participants reported their medical history (yes/no) regarding pre-
vious cardiovascular diseases (myocardial infarction, stroke, or angina
© 2014 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Flow chart of the heart failure (HF) study recruitment and follow-up.
pectoris), cancer, asthma, diabetes mellitus, other endocrine disorders
(hypothyreosis, hyperthyreosis, goitre, or thyroiditis), musculoskeletal
disorders (osteoporosis, fibromyalgia, or arthrosis/arthritis), autoim-
mune disease (Bechterew disease or rheumatoid arthritis), epilepsy,
or other chronic disease. Those who answered ‘yes’ to one or more
of these questions were categorized as having a chronic disease.
Clinical examination
Clinical examinations were performed by trained nurses according to a
standardized protocol and included measurements of blood pressure,
heart rate, weight, height, and waist and hip circumference. Heart rate,
and systolic and diastolic blood pressures were measured after the
participant had been seated for at least 2min with the cuff on, with cuff
size adjusted for arm circumference.30 Blood pressure and heart rate
measurements were performed with the Dinamap 845XT (Criticon)
based on oscillometry and automatically involved three recordings at
1-min intervals. The first heart rate recording was on average 2 b.p.m.
lower than the second and third measurement and was thus used
in order to mirror resting heart rate. For blood pressure, the value .
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.. decreased for each recording, thus we used the average of the second
and third blood pressure readings. Height was measured without shoes
to the nearest 1.0 cm and weight with light clothing to the nearest
0.5 kg.30 Body mass index (BMI) was computed as weight (in kg) divided
by the squared value of height (in metres).
Blood sampling and laboratory measurements
A non-fasting whole blood sample was drawn from each partici-
pant, recording the time between the last meal and the venepunc-
ture. Serum was separated by centrifugation at the screening site
and immediately placed in a refrigerator. The samples were sent (the
same day, or the following Monday for samples drawn on Friday)
for analyses at the central laboratory at Levanger Hospital, Nor-
way, where a Hitachi 911 Autoanalyzer was used, applying reagents
from Boehringer Mannheim, Germany. Serum total cholesterol was
measured by an enzymatic colorimetric cholesterol esterase method
and serum creatinine by the Jaffé method. The day-to-day coeffi-
cient of variations were 1.3–1.9% for total cholesterol and 3.5% for
creatinine.8
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Statistical analysis
We used Cox proportional hazard models to examine the associations
of symptoms of depression and anxiety with subsequent risk for HF
and hazard ratios (HRs) with 95% confidence intervals (CIs). All the
models were analysed both using a categorical approach and estimating
risk per unit increase on the different HADS scores. For test of trends
between increasing anxiety and depression symptom level, a numeric
value of 0–2 was assigned to the HADS categories, with 0 having
no, 1 having moderate, and 2 having severe symptoms of anxiety
or depression, treating the categories as a continuous variable. In a
separate analysis, we calculated the risk for HF associated with the
presence of MSAD in HUNT 1 and HUNT 2 when those without
symptoms of MSAD in both of the surveys constituted the reference
group.
We used directed acyclic causal graphs to summarize visually hypo-
thetical relationships among variables of interest.29 Model 1, adjusted
for age as a continuous variable and sex, is the best for assessing causal-
ity. Models 2–5 include variables that may act as both confounding and
mediating factors for the association of depression and anxiety with HF
risk. Model 2 included potentially socio-economic confounders, such
as education and marital status. In model 3, established cardiovascular
risk factors such as high heart rate, high blood pressure, low physical
activity, high BMI, smoking, dyslipidaemia, alcohol intake, diabetes mel-
litus, and serum creatinine were added. Model 4 tested whether AMI
prior to baseline data collection influenced the estimates. Finally, the
full multivariable model tested if AMI during follow-up influenced the
estimates, and included AMI during follow-up as a time-dependent vari-
able (model 5). For the 2522 non-responders on the HADS question-
naire, we examined HF incidence and the distribution of the variables
included in the statistical models.
Several stratified analyses were conducted to assess whether the
association of anxiety and depression and risk for HF could be modified
by other factors. We investigated the potential effect of modification
by sex, age (dichotomized at age 50 and age 65), BMI (dichotomized at
≥35 kg/m2), total cholesterol (dichotomized at 6.5mmol/L), education
(dichotomized at 12 years), blood pressure (systolic blood pressure
dichotomized at >140mmHg, diastolic blood pressure at >90mmHg),
smoking status (current vs. no current smoking), alcohol consumption
(heavy drinking vs. no heavy drinking), and previous AMI (yes/no). We
also formally tested the homogeneity of stratum-specific relative risks.
For these tests of interaction, we used the trend variable as defined
above.
Several sensitivity analyses were performed to assess the robustness
of our findings. First, as AMI is a known risk factor for HF and is also
associated with depression and anxiety symptoms, we performed an
additional analysis restricted to those without known AMI at baseline.
Next, we analysed the risk restricted to diabetic patients. Thereafter,
we excluded participants with one or more of the following co-morbid
physical illnesses: previous myocardial infarction (AMI), stroke, angina
pectoris, cancer, asthma, diabetes mellitus, other endocrine disorders,
musculoskeletal disorders, autoimmune diseases, and other chronic
diseases.
Secondly, in additional analysis, we restricted cases to those HF
cases that were confirmed at the hospital; thus, cases whose HF
diagnosis were based on death certificates alone were excluded from
the analyses.
Finally, in order to address the possibility of reverse causation
as an explanation for possible associations, we excluded the first 5
years of follow-up and repeated the analyses. All sensitivity analyses
were run in the full multivariable model including previous AMI and ..
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.. adjustment for incident AMI during follow-up as a time-dependent
covariate.
We tested the proportionality of hazard using log–log curves
and formal tests of interaction with time or log-time. There was
no evidence against the proportionality assumption in our models.
Statistical analyses were performed in Stata IC/12.1 for Windows
(©Stata Corp LP).
Results
Characteristics of the study population at baseline, by HF status
during follow-up, are shown in Table 1. Among those who did
not respond to the HADS questionnaire, the HF incidence in
the 11.4 years was 8.7%, probably mainly because they were
older (mean 66.4 years) at baseline, and in addition had a more
unfavourable cardiovascular risk profile, including higher blood
pressure on average, than the total study population. Among
the 63 567 study participants, 1499 participants (2.4%) developed
HF during an average of 11.3 years (SD 2.9) of follow up. Of
these, 1245 HF cases were diagnosed and included in the hospital
registers, and 254 were registered by the National Cause of Death
Registry alone. The participants that developed HF were older
at baseline examination and more likely to have diabetes, higher
systolic and diastolic blood pressure, be inactive, to live alone, have
lower education, be alcohol abstainers, and score higher on the
HADS-D subscale. They also had a higher incidence of incident
AMI (14%) during follow-up, compared with those who did not
develop HF (2.5% incident AMI).
Using the highest cut-off (HADS ≥11), the prevalence rates
were 3.2% and 5.1% for depression and anxiety symptoms, respec-
tively. This estimate is comparable with the prevalence of diag-
nosed depression and anxiety disorders in the general population
in Europe.31 These participants were more likely to be female,
less educated, inactive, current smokers, alcohol abstainers, and
report a history of previous AMI than those in the reference
group.
Table 2 presents the age- and sex-adjusted HRs and several
multivariable adjusted HRs for incident HF in relation to symptoms
of depression, anxiety, and MSAD. There was no excess risk
for future HF associated with symptoms of anxiety in the crude
model, adjusted for sex and age (HR 1.17, 95% CI 0.90–1.15).
For MSAD, the moderately increased risk for HF observed in
model 1 (HR 1.34, 95% CI 1.04–2.07) was explained by traditional
cardiovascular factors in model 3 (HR 1.09, 95% CI 0.81–1.46).
For depression, the age- and sex-adjusted HRs for HF were 1.11
(0.95–1.30) for moderate symptoms and 1.46 (1.19–1.80) for
severe symptoms (P for trend 0.000). These associations for severe
symptoms were only slightly attenuated after further adjustments
for socio-economic status, an established cardiovascular risk factor
(HR 1.37, 95% CI 1.04–1.81). Additional adjustment for previous
and time-dependent incident AMI during follow-up did not further
attenuate the risk for HF associated with severe symptoms of
depression (HR 1.41, 95% CI 1.07–1.87). The results from the
analysis using the risk per unit HADS score approach did not differ
from the categorical approach; taking HADS-D as an example, with
a 1.03 increased risk associated with each unit rise in HADS-D
© 2014 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Baseline characteristics of the participants according to heart failure during follow-up
n HF during follow-up, % (n) No HF during follow-up, % (n)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Total 62 567 2.4 (1499) 97.6 (61 068)
Variable
Sex (male) 62 567 50.6 (759) 46.7 (28 559)
Diabetes mellitus 62 448 12.7 (188) 2.6 (1562)
Smoking 62 344
Never 28 313 45.4 (674) 45.4 (27 639)
Former 15 675 32.7 (485) 24.9 (15 190)
Current 18 356 21.9 (1485) 29.6 (18 030)
Physical activity 56 993
Inactive 22 255 60.9 (676) 38.6 (21 579)
Moderately active 29109 34.7 (385) 51.4 (28 724)
Physically active 5629 4.4 (49) 9.9 (5580)
Living alone 62 425 43.9 (659) 39.4 (24 007)
Education 60 270
≤9 years 21 629 71.6 (942) 35.1 (20 687)
10–12 years 26 443 22.4 (295) 44.4 (26 148)
>12 years 12 198 5.9 (78) 20.6 (12 120)
Alcohol 58,986
Abstainer 23 640 71.2 (975) 39.3 (22 665)
Light drinker 27 298 23.7 (325) 46.8 (26 973)
Moderate drinker 6196 3.8 (52) 10.7 (6144)
Heavy drinker 1852 1.2 (17) 3.2 (1835)
Previous myocardial infarction 1871 21.7 (322) 2.5 (1549)
Myocardial infarction during follow-up 1739 14.0 (210) 2.5 (1529)
Variables, mean (SD) n Mean (SD) Mean (SD)
Age, years 62 567 73.6 (9.7) 48.7 (16.6)
BMI, kg/m2 61 956 27.9 (4.6) 26.3 (4.1)
Heart rate, b.p.m. 62 235 73.3 (14.6) 71.3 (13.1)
Systolic BP, mmHg 62152 156.6 (25.9) 136.9 (21.2)
Diastolic BP, mmHg 62152 85.5 (12.1) 80.0 (12.0)
Total cholesterol, mmol/ L 62 216 6.4 (1.3) 5.9 (1.3)
HDL cholesterol, mmol/L 62 195 1.3 (0.4) 1.4 (0.4)
Triglycerides, mmol/L 62 215 2.1 (1.2) 1.7 (1.1)
Serum creatinine, mmol/L 62 214 97.6 (22.6) 87.5 (15.0)
HADS-Depression score 62 414 4.6 (3.5) 3.5 (3.3)
HADS-Anxiety score 61 335 3.8 (3.4) 4.3 (3.3)
HADS-Total score 61182 8.4 (6.0) 7.7 (5.6)
ADI-Total score in HUNT 1 36 418 13.6 (1.3) 13.5 (1.2)
ADI, Anxiety and Depression Index; BMI, body mass index; BP, blood pressure; HADS, Hospital Anxiety and Depression Scale; HF, heart failure.
score, a person with a score of 8 will have 1.039 times, i.e 30%,
increased risk compared with a person that scores 0. Figure 2 shows
the Kaplan–Meier curves for incident HF according to depression
symptom categories; depressive symptoms were associated with
higher risk for HF in a dose–response manner consistently during
the follow-up.
Table 3 displays the risk for HF with MSAD in HUNT 1 and
2. Those who reported MSAD in both HUNT 1 and 2 had an
HR of 1.47 (95% CI 1.04–2.07) for HF in model 1 compared
with those who did not experience MSAD in any of the health
surveys. This relative risk for HF was, however, largely explained by
cardiovascular risk factors (HR 1.18, 95% CI 0.73–1.87). Further
adjustments for previous AMI and time-dependent incident AMI
during follow up did not lead to further attenuation. ..
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. We found no statistical evidence for any effect modification for
any of the stratified variables including sex, age, education, smoking
status, BMI, total cholesterol, physical activity, and blood pressure.
Sensitivity analysis
Supplementary material online, Table S1 presents the multivariable
adjusted HRs for HF in relation to symptoms of depression, anxiety,
and MSAD in different sensitivity analyses.
A total of 52 202 participants completed the questionnaire on
common chronic somatic disease. Of these, 16 072 reported hav-
ing at least one chronic somatic disease. Diabetes was six-fold
more prevalent in those who later developed HF, and this war-
ranted a separate analysis; in the 1750 diabetic participants, ≥11
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Table 2 Hazard ratios (95% confidence intervals) for heart failure during follow-up according to symptoms of
depression and anxiety, and mixed symptoms of anxiety and depression in HUNT 2 (1995–1997).
Variable Model 1 Model 2 Model 3 Model 4 Model 5
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
HADS-D Events/person-years 1492/703 766 1310/679 612 905/597 200 900/596 685 900/596685
0–7 Reference Reference Reference Reference Reference
8–10 1.11 (0.95–1.30) 1.10 (0.93–1.30) 1.07 (0.87–1.32) 1.07 (0.87–1.31) 1.08 (0.88–1.33)
≥11 1.46 (1.19–1.80) 1.51 (1.21–1.89) 1.38 (1.04–1.83) 1.41 (1.06–1.86) 1.41 (1.07–1.87)
P for trend 0.000 0.001 0.034 0.028 0.023
Risk per unit increase in the
HADS-D scale
1.03 (1.02–1.05) 1.03 (1.02–1.05) 1.03 (1.01–1.05) 1.03 (1.01–1.05) 1.03 (1.01–1.05)
HADS-A Events/person-years 1366/693 483 1224/671 888 869/593199 864/592 694 864/592694
0–7 Reference Reference Reference Reference Reference
8–10 1.12 (0.93–1.34) 1.15 (0.95–1.40) 0.88 (0.69–1.13) 0.88 (0.69–1.13) 0.90 (0.70–1.15)
≥11 1.17 (0.90–1.15) 1.07 (0.80–1.43) 0.95 (0.67–1.35) 0.98 (0.69–1.40) 1.00 (0.70–1.43)
P for trend 0.105 0.221 0.431 0.560 0.643
Risk per unit increase in the
HADS-A scale
1.01 (0.99–1.03) 1.01 (0.99–1.02) 1.01 (0.99–1.03) 1.01 (0.99–1.03) 1.01 (0.99–1.03)
HADS-T Events/person-years 1359/691 950 1219/670 617 868/592 540 869/592 035 863/592035
0–15 Reference Reference Reference Reference Reference
15–19 1.09 (0.90–1.33) 1.17 (0.91–1.37) 1.18 (0.92–1.49) 1.15 (0.90–1.46) 1.16 (0.91–1.48)
≥19 1.34 (1.04–2.07) 1.31 (1.04–1.66) 1.10 (0.82–1.48) 1.18 (0.87–1.58) 1.20 (0.89–1.61)
P for trend 0.018 0.015 0.248 0.151 0.114
Risk per unit increase in the
HADS-T scale
1.01 (1.00–1.02) 1.01 (1.00–1.02) 1.01 (0.99–1.02) 1.01 (1.00–1.02) 1.01 (1.00–1.03)
HADS, Hospital Anxiety and Depression Scale. HADS-T, was calculated by summing up valid HADS-A and HADS-D into HADS-total scores.
Model 1: adjusted for calendar age and sex.
Model 2: model 1+marital status, education.
Model 3: model 2+ smoking, physical activity, body mass index, total cholesterol, diabetes mellitus, resting heart rate, systolic blood pressure, alcohol, serum creatinine.
Model 4: model 3+ previous myocardial infarction.
Model 5: model 4+ time-dependent adjustment for acute myocardial infarction during follow-up.
Figure 2 Kaplan–Meier curve of incident heart failure during
follow-up according to depression category. HADS-D, Hospital
Anxiety and Depression Scale, depression subscale.
in depression score constituted a 70% (95% CI 1.03–2.80) higher
risk than for those who scored <8. This high risk in the diabetic
population was mainly explained by cardiovascular risk factors in
model 3, where the risk dropped to 23%. After exclusion of all
common chronic somatic diseases, 305 were diagnosed with HF
during follow-up, and the risk of HF in people free of chronic .
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. diseases related to symptoms of depression slightly increased. Of
special interest, the risk associated with symptoms of depression,
after excluding participants with self-reported previous AMI before
HUNT 2 (n=1253), was only reduced by ∼10% (HR 1.33, 95% CI
0.88–2.01) in the full multivariable model including adjustment for
time-dependent incident AMI during follow-up.
When follow-up was restricted to HF events confirmed in
hospitals (1073 events) and HF cases emerging after the first
5 years of follow-up (692 events), the risk for HF related to
symptoms of depression remained virtually unchanged. The risk
for HF associated with MSAD in HUNT 2 and repeated MSAD
in HUNT 1 and 2 was elevated in hospitalized confirmed HF
compared with the total HF sample, and lower after exclusion of
the first 5 years of follow-up.
Discussion
In this large prospective study of a general population free from
known HF at baseline, we found that symptoms of depression,
but not those of anxiety or MSAD, were associated with a
dose–response increased risk for incident HF. This risk remained
essentially unchanged after adjustment for demographic vari-
ables, established cardiovascular risk factors, previous AMI, and
time-dependent adjustment for incident AMI during follow-up. The
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Table 3 Hazard ratios (95% confidence intervals) for heart failure during follow-up according to episodes of mixed
symptoms of anxiety and depressionin HUNT 1 and HUNT 2.
No. of episodes of MSAD Model 1 Model 2 Model 3 Model 4 Model 5 651/29616
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Events/person-years 1021/406071 910/392118 654/344 334 651/29 616
Never MSAD Reference Reference Reference Reference Reference
MSAD once 1.12 (0.98–1.27) 1.09 (0.95–1.24) 1.03 (0.88–1.20) 1.05 (0.89–1.22) 1.05 (0.90–1.23)
MSAD twice 1.47 (1.04–2.01) 1.53 (1.06–2.20) 1.30 (0.83–2.06) 1.21 (0.76–1.93) 1.21 (0.76–1.93)
P for trend 0.018 0.048 0.441 0.426 0.385
MSAD, mixed symptoms of anxiety and depression.
Model 1: adjusted for calendar age and sex.
Model 2: model 1+marital status, education.
Model 3: model 2+ smoking, physical activity, body mass index, total cholesterol, diabetes mellitus, resting heart rate, systolic blood pressure, alcohol, serum creatinine.
Model 4: model 3+ previous myocardial infarction.
Model 5: model 4+ time-dependent adjustment for acute myocardial infarction during follow-up.
association also remained robust in several additional sensitivity
analyses.
Comparison with previous studies
Previously, the association between anxiety symptoms and
future HF has been investigated in one study of American vet-
erans, where the authors found a 1.19 (95% CI 1.10–1.28)
increased age-adjusted hazard associated with anxiety disorders
and post-traumatic stress disorder.17 This point estimate is com-
parable with the 1.17 (95% CI 0.90–1.15) hazard for future HF
associated with a score of ≥11 on the HADS-A subscale in our
study. The US study has a larger sample size, with 236 079 partici-
pants, which may explain the difference in precision between the
two studies.
Symptoms of depression and risk for future HF have mostly
been investigated in smaller studies and/or in selected samples, and
conclusions have been conflicting.4–8,17 Two studies found negative
results between symptoms of depression and HF: the first of these
was the ‘Established population for epidemiologic studies of the
elderly’ (EPESE, n= 1749), conducted in 1999.5 However, in that
study, Chen et al. seem to have discarded symptoms of depression
as a risk factor for HF based on P-values from 𝜒2 and t-statistics,
which do not account for time to event. The second negative
results were reported in 2011 from ‘The cardiovascular health
study (CHS)’ population, who at baseline were on average 79 years
old but free of HF (n= 4114). Afro-American people reported
more depression (30%) compared with white people (18.7%)
in the CHS study, yet the distribution of confirmed HF events
between the ethnic groups was not reported. Based on well known
differences in health status and access to health services across
ethnical groups in the USA, this is a limitation of the otherwise
well performed study.32 In contrast, we had a homogenous study
population from Norway, where healthcare coverage is universal,
and free healthcare system access exists across socio-economic
groups.32
Conversely, three small-scale studies with potential methodolog-
ical problems reported increased risk for HF with depressive symp-
toms. ‘The Finland, Italy and Netherlands Elderly’ (FINE study), .
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.. which included only men (n= 799), found a 1.16 increased hazard
for each five steps in the Zung depression rating scale.6 Another
study, ‘the Systolic Hypertension in the Elderly Program’ in the
USA, had short follow-up of 4538 persons above 65 years with
hypertension,4 i.e inclusion of only persons predisposed for HF,7
found a 2.59 increased risk for future HF. The third study, also from
EPESE, found a 52% increased risk for future HF associated with
symptoms of depression, but only for the women in the sample. In
contrast, our study included a large community sample with both
sexes and long follow-up which allowed for exclusion of the first
5 years of follow-up, which increases the possibility of detecting
reverse causation. Further, we used statistical models that allowed
for time to event and we tested our model carefully for violations
against the proportionality of hazard assumptions.
Unfavourable socio-economic and behavioural lifestyles may be
a link between symptoms of depression and increased HF risk.
Symptoms of depression, but not as much symptoms of anxiety,
are often strongly associated with traditional risk factors for HF,
such as lower education, physical inactivity, unhealthy diet, obesity,
and poorer lifestyle.1,33,34 Some of these behaviours associated with
loweredmood, such as inactivity, obesity, and smoking, are also sug-
gested to be sources of an inflammatory process that can cause HF,
and reciprocally also cause depression.35 In our study, people with
the most severe symptoms of anxiety and depression had a more
unfavourable socio-economic and cardiovascular profile. However,
the adjustment for socio-economic factors and established cardio-
vascular risk factors only attenuated the relative risks in relation to
symptoms of anxiety and MSAD, but not for depressive symptoms.
Ischaemic heart disease is a major cause of HF, and IHD is closely
linked to symptoms of depression.36–38 However, in our analyses,
cardiovascular risk factors and AMI prior to baseline explained
only 10–13% of the risk point estimate for HF in association with
depressive symptoms. Time-dependent adjustment for incident
AMI during follow-up did not attenuate the risk any further. Other
chronic somatic diseases did not explain the association either, and
the risk for HF associated with symptoms of depression increased
when we excluded these chronic disorders. In diabetic patients,
for example, the crude risk for HF associated with depression
symptoms was high (70%) but, after adjustment for cardiovascular
© 2014 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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risk factors, only a 23% increased risk remained. It is well known
that over a certain amount of time, the strength of the effect
of a given factor on disease occurrence may change because
the prevalence of its causal complement in various mechanisms
also changes.29 It is therefore likely that participants with chronic
diseases such as diabetes have different distributions of the other
component causes, i.e cardiovascular risk factors, compared with
the general population.
Strengths and study limitations
The large sample size and the life span perspective, together
with long follow-up are amongst the most important strengths
of this study. Furthermore, the HUNT catchment area has a low
net migration (<0.3% net migration/year) and close to complete
follow-up at the local hospitals.
Nevertheless, the study also has some important limitations.
Similar to other prospective studies of risk for HF associated with
symptoms of depression, we did not assess depression and anxi-
ety disorders, but relied on self-reported symptoms. The HADS
questionnaire, which was used in HUNT, does not mirror somatic
depressive symptoms such as fatigue, weight loss, and insomnia,
which greatly overlap with HF symptoms.15,22 However, by using
this approach, some depression cases with predominantly somatic
symptoms may go undetected. Thus, it is more likely that our esti-
mate for the association between symptoms of depression, anxiety,
and MSAD with future HF is underestimated than overestimated.
Even though we found no evidence of excess risk for HF in partici-
pants who reported symptoms of anxiety and depression in HUNT
1, ten years prior to baseline, compared with those who did not,
our study cannot conclude whether there is a dose–response rela-
tionship between the number of episodes of symptoms of anxiety
and depression, and HF risk.
Further, depressive symptoms have been shown to be associated
with low adherence to treatment, drug, and medical advice.1,39–42
The Norwegian prescription registry was established in 2004,
and the HUNT 2 study does not have access to reliable data
about all participants’ medications. It is important to distinguish
treatment by tricyclic antidepressant which are known to cause
adverse cardiovascular effects from by selective serotonin reup-
take inhibitors (SSRIs) that are associated with effects that are
favourable in lowering cardiovascular risk.43 Therefore, poor medi-
cal adherence might be a potential mechanism that remained unde-
tected in our study. However, in the only large-scale study of risk
for HF with major depressive disorder, the observed age-adjusted
risk of 1.21 (1.13–1.28) increased to 1.56 with adjustment for
psychotropics.17 The same US study also found a protective effect
of psycotropics for symptoms of anxiety and MSAD, where the
point estimate increased from 1.19 to 1.46 and 1.24 to 1.74,
respectively. Also for depressive symptoms, other studies indicate
that treatment including psychotropics44,45 protects depressed per-
sons for future cardiovascular disease risk rather than confounding
the relationship.
Increased neurohormonal stress activity and inflammation have
also been linked to development of depression.1 Symptoms of
depression may in turn up-regulate and worsen the neurohormonal ..
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.. regulation of heart rate, blood pressure, and obesity, which are
all central mechanisms in the development of HF.1,16,46–48 In
contrast, anxiety symptoms showed a weaker association with
future HF in the current cohort. It may be hypothesized that
low intensity anxiety, such as worry and tension, as measured by
HADS-A, activates proinflammatory cytokines or neurohormonal
stress activity less than diagnostic categories of anxiety, such as
panic disorders and agoraphobic disorder. These latter conditions
manifest with intense physiological activation and are found to
increase overall morbidity.49 Furthermore, symptoms of anxiety
often act as a precursor for depressive symptoms, and of the
two conditions depression is often found to be the largest driving
factor in mortality studies.39 Unfortunately, the HUNT study did
not analyse markers of increased neurohormonal activity, and
inflammatory activity was only analysed for a small subpopulation;
therefore, we were not able to test these hypothetical links
between depressive symptoms and future HF.
Identification and ascertainment of HF diagnostics might be
misclassified. However, the overall quality and reliability of the
hospital discharge registers of HF is high in Nordic Countries.27,50
In line with Nordic recommendations and to ensure optimal
precision, only those with a primary diagnosis of HF were included
in the analyses.25,27,50 From January 1995 to December 2008, a
total of 1958 patients (≥18 years of age) were diagnosed with HF
in the two hospitals of Nord-Trøndelag County. Of these, only
29 (1.6%) were diagnosed outside the Departments of Internal
Medicine/Cardiology. Thus, 98.4% of the total HF patients received
their hospital diagnosis in a setting where cardiologists were central
in the diagnostics, ensuring a high sensitivity and specificity. Data
from the Cause of Death Registry have somewhat lower reliability
than the hospital discharge register of the HF diagnosis,25 as
many of these deaths are probably sudden. However, even if we
do not know which proportion of the deaths were sudden, we
obtained essentially the same effect by restricting the study to
hospital-verified HF cases, and therefore it seems unlikely that the
lower reliability of HF deaths could explain our findings.
Conclusion
Symptoms of depression, but not symptoms of anxiety or MSAD,
were associated with increased risk for HF in a dose–response
manner in this general population sample. The increased risk
could not be directly explained by established cardiovascular risk
factors or by prevalent or incident AMI. Prevention and treatment
strategies for depressive symptoms might have the potential to
reduce development of cardiovascular disease, including HF, and
should therefore be carried out on a population level and in
primary care settings, not only in patients with established HF
or cardiovascular disorders. In both community51 and hospital
samples,52 anxiety often co-exists and worsens the course of
depressive symptoms, and it is recommended to consider both
conditions when planning appropriate management strategiesl.53
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Table S1. Risk for HFAssociated with Symptoms of Anxiety and Depression in Sensitivity Analyses.       
 Exclusion of All Chronic 
somatic diseases 
Restriction to Hospital Verified HF 
(1073 events * 
HADS-D   
    Events/ person-years 212/ 373909 656/597292 
    Cut off 8–10 1.25 (0.81–1.91) 0.99 (0.77–1.27) 
    Cut off 11 1.57 (0.79–3.08) 1.46 (1.05–2.01) 
    P for trend 0.114 0.084 
CONTINOUS SCALE 1.05 (1.01–1.10) 1.02 (1.00–1.05) 
HADS-A   
   Events/ person years 207 (373069) 629/ 593291 
   Cut Off 8–10 0.73 (0.39–1.39) 0.89 (0.67–1.18) 
   Cut off 11 0.75 (0.24–2.38) 1.04 (0.69–1.55) 
   P for trend 0.337 0.742 
CONTINOUS SCALE 1.01 (0.96–1.06) 1.01 (0.98–1.03) 
HADS-T   
   Events/ person years 207/ 372784 628/592632 
   Cut Off 15–19   1.30 (0.76 – 2.14) 0.98 (0.72–1.32) 
   Cut Off 19 0.81 (0.29–2.18) 1.25 (0.89–1.74) 
   P for trend 0.811 0.305 
CONTINOUS SCALE 1.02 (0.99–1.05) 1.01 (1.00–1.02) 
MSAD (HUNT 1 and 2)   
   Events /person years 157/200695 467/344398 
   One episode MSAD 1.09 (0.79–1.50) 1.11 (0.92–1.34) 
   Two episode MSAD    1.22 (0.30–5.02) 1.34 (0.79–2.27) 
P for trend 0.533 0.166 
*Joint effect of persons that reported previous myocardial infarction, previous other coronary disease like
diabetes, other endocrine disorders, musculoskeletal disorders, autoimmune diseases, epilepsy, cancer and
analysis are preformed in model 5 with adjustment for startage, sex, Marital Status, Education,  Smoking,
Total Cholesterol, Diabetes Mellitus, Systolic Blood pressure, se-Creatinine, Alcohol, Previous myocardi
adjustment for myocardial infarction during follow up. 
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Abstract  
Aims  
Symptoms of anxiety and depression often co-exist with heart failure, yet little is known about 
the association with left ventricular (LV) subclinical dysfunction. We aimed to study the 
associations of single and repeated self-reported depression and anxiety symptoms on the 
Hospital Anxiety and Depression Scale (HADS) with sensitive indices of LV systolic and 
diastolic function based on Tissue Doppler (TD) and Speckle Tracking (ST). 
Methods and results  
In the third wave of the Nord-Trøndelag Health Study (HUNT3, 2006-2008) 50,810 (54% of 
invited) participated at a baseline examination. A random selection of 1296 persons whom 
where free from known cardiovascular disease, hypertension and diabetes at baseline 
underwent echocardiography. Of these, 1034 had answered the HADS questionnaire in 
HUNT 3 and 700 had additionally answered the HADS in HUNT2 (1995–1997) ten years 
earlier. Baseline depression and anxiety symptoms were not associated with a reduction in LV 
indices. A 5 unit increase in the additive depression scores from HUNT2 and HUNT3, but not 
additive anxiety score, where associated with a reduction in early diastolic annular velocity 
(e´); -5.5% (95% CI -9.6%, -1.5%) for women and -5.0% (95% CI -8.6%, -1.3%) for men.  
Conclusion  
The additive effect of two repeated depression scorings indicates lower LV diastolic function 
measured by e´ at follow-up among healthy participants. Thus, long lasting depression 
symptoms should be taken into account when discussing subclinical LV dysfunction. 
Key words: Echocardiography, Epidemiology, Risk factors, Depression, Anxiety 
Introduction  
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Even though depression and anxiety symptoms are associated with increased risk for CVD (1-
6) little is known about their influence on subclinical cardiac dysfunction. Decades ago the 
hypothetical link between depression symptoms and left ventricular (LV) subclinical 
dysfunction was disregarded based on no association with ejection fraction (7), a measure 
which today is acknowledged with limited ability to reveal subtle LV dysfunction (8). 
However, novel methods of assessing LV function, including assessment of tissue velocities 
and deformational changes of the myocardium through the cardiac cycle, have been shown to 
be sensitive in detecting subtle subclinical dysfunction related to specific diseases or 
conventional risk factors such as age, BMI, non HDL cholesterol (9-11). To the best of our 
knowledge, no study exists on the association between anxiety symptoms and subclinical 
cardiac dysfunction measured by echocardiography or magnetic resonance imaging, and only 
one study with symptoms of depression. That one study included people with hypertension, 
diabetes and metabolic syndrome (12). Subclinical cardiac disease or the presence of 
cardiovascular risk factors may trigger inflammatory activity or neurohormonal actions that 
trigger both the depressive symptoms (13-15) and cause the process of early LV remodeling. 
Thus, the positive associations of depression symptoms with LV dysfunction in the Korean 
study may to some degree reflect reverse causality (12).  
Therefore, the aim of this study was to investigate cross sectional associations with 
single and repeated anxiety and depression symptom levels with sensitive indices of LV 
systolic and diastolic function based on Tissue Doppler (TD) and Speckle Tracking (ST) 
echocardiography in 1034 Norwegian healthy adults who participated in the third wave of the 
Nord-Trøndelag Health Study (HUNT3).   
 
Methods 
Study population and setting 
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All 93,210 adult citizens aged 20 years in Nord-Trøndelag County, Norway, received a 
postal invitation to participate in the third wave of HUNT (HUNT3, 2006–2008, 
http://www.ntnu.edu/hunt). In total, 48,289 (52%) people participated. Within the HUNT3 
study, the Echocardiographic study was conducted in a random selection of 1266 subjects free 
from known CVD, diabetes or hypertension. The random selection process took place when 
the participants attended a baseline clinical examination at the study centres and the 
echocardiographic examinations were performed at this visit. The study size for the 
echocardiography study was based on suitability in order to obtain normal reference values of 
the different LV indices by age groups (9, 16-18). The participants also gave self-report on 
standardised questionnaires (http://www.ntnu.edu/hunt/data/que) in the HUNT3 study  
Earlier, in the second wave of the HUNT study (HUNT2), which was conducted in 
1995-1997, 95,147 persons were invited and 65,215 (69%) participated. Details about the 
HUNT study have been published by Krokstad et al. (2013) (19). The study was approved by 
the regional committee for medical and health research ethics, and by the HUNT Publication 
Board.  
 
Exposure: Symptoms of anxiety and depression.  
At the examination the attendees received Questionnaire 2 (Q2), which was taken home, filled 
in and returned in a prepaid envelope. On Q2, the participants reported symptoms of anxiety 
and depression during the last week using the Norwegian version of the HADS. Seven 
depression questions mainly mirror depressed mood or reduced pleasure response affect 
(anhedonia), as well as psychomotor retardation (HADS-D), and seven anxiety questions 
mirror mostly symptoms of worry and restlessness (HADS-A) (20). Each subscale have a 4-
point Likert scale, ranging from 0 (no symptom) to 3 (highest symptom level), which add up 
to a score range from 0 to 21 points. Valid HADS-D and HADS-A scores where defined if 5 
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or more of the questions were answered on each subscale. Missing response among those who 
filled in 6 or 5 items where replaced based on the sum of completed items multiplied by 7/6 or 
7/5, respectively. In total, 1034 persons from the echocardiographic study (544 women) had 
valid HADS symptom scores from baseline in HUNT3 and thus constitute the study 
population in this study (see Figure 1 Flow chart).  
Insert Figure 1 Flow chart about here 
Previous HADS symptoms were available for 700 individuals (357 women, i.e 68 %) 
from their participation in HUNT2. We summed each participants´ HADS-D and HADS-A 
scores from HUNT2 and HUNT3 in order to reflect the additive sum of depression (HADS-
DA) and anxiety symptom scores (HADS-AA) from both waves.  We used the observed score 
range for all HADS-measurements in the statistical models, i.e a theoretical range of 0-21 for 
HADS-A and HADS-D in HUNT3 and 0-42 for the additive score of depression and anxiety 
symptoms in HUNT2 and HUNT3.  
 
Covariates 
Demographic and lifestyle factors 
Demographic and lifestyle factors were assessed from the baseline examination, in HUNT3. 
Marital status was categorized into never married, married or living with partner, or 
separated/divorced/widowed.  
Education was categorized as low ( 9 years), medium (10 to 12 years) or high (> 12 
years). Smoking habits were categorized as current, previous or never smoking. A validated 
index for leisure-time physical activity was calculated as a product of exercise frequency, 
exercise intensity and training session duration (21). 
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Clinical examination 
A clinical examination was performed by trained nurses at baseline examination in HUNT3 
according to a standardised protocol (19). Systolic and diastolic blood pressures were 
measured three times after the participant had been seated for at least two minutes with the 
cuff on, with cuff size adjusted for arm circumference. All blood pressure measurements were 
performed with the Dinamap 845XT (Criticon) based on oscillometry. The average of the 
second and third measurement was used in the analyses. Height was measured without shoes 
to the nearest 1.0 cm and weight with light clothing to the nearest 0.5 kg. Body mass index 
(BMI) was computed as weight (in kg) divided by the squared value of height (in meters) 
(19).  
 
Echocardiographic Acquisition, analyses and reproducibility 
The participants waited at least one hour without smoking or eating at the study site before the 
echocardiography, and the mean time since last meal was 2.7 (SD 2.1) hours for women and 
2.8 (SD 2.0) hours for men (9).All examinations were conducted by an experienced physician 
echocardiographer (HD) and the participants were examined in the left lateral decubitus 
position with a high- end Vivid 7 scanner (version BT06; GE Vingmed Ultrasound AS, 
Horten, Norway) using a phased-array transducer (M3S and M4S). All the presented 
echocardiographic measurements were available in 96% of the participants (16). All 
echocardiographic data were stored digitally and analysed subsequently (9, 16-18). 
LV function was assessed by the several well-established echocardiographic indices 
of systolic and diastolic longitudinal function. LV end-systolic global strain (global strain) 
refers to percentage longitudinal shortening of the myocardium of the LV during systole, and 
LV peak global strain rate (global strain rate) to the respective maximal speed of global strain. 
Both indices are presented as the average of segmental values when assessed in a 16 segment 
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model of the LV (16). We used a customized software (GcMat; GE Vingmed Ultrasound, 
Norway) with a combination of TD for tracking along the ultrasound beam and ST (tracking 
of grey-scale speckles) for tracking perpendicular to the ultrasound beam (9). Further, peak 
mitral annular systolic velocity (S’) and peak mitral annular early diastolic velocities (e’) were 
measured in the base of the LV wall by pulsed waved TD and the average of the septal, 
lateral, anterior, and inferior locations was used in the analyses. Correspondingly, mitral 
annular plane systolic excursion (MAPSE) was measured as the average of the total systolic 
cumulative excursion of the same locations. Ejection fraction (EF) was analysed by 
calculation of end-diastolic and end-systolic LV volumes from tracings in the four and two 
chamber view (9). The average heart rate during echocardiography was used in the analysis. 
The reproducibility of the echocardiographic measures has been described elsewhere 
(18). Briefly the interobserver mean errors were 4–8% and intraobserver mean errors were 2-
5% for indices of LV function (9).  
 
Statistical analysis 
Clinical echocardiographic data followed a normal distribution and is presented as mean (SD). 
Characteristics by gender is presented in mean (SD) for continuous variables and as numbers 
(%) for categorical data. Associations of symptoms of depression and anxiety with LV 
function were estimated by multivariate linear regression analyses with the different LV 
function indices as dependent variables as all LV function indices were mutually correlated (r 
0.21–0.61, all p<0.001). The LV function measures were log transformed, and the partial-
regression coefficients are presented as the percentage difference in LV function per specified 
5 units difference in HADS-score with the corresponding 95% confidence intervals.  
Spearman correlations were performed between all HADS-measures and LV function 
measures. All our linear regression models were adjusted for age and heart rate during 
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echocardiography as a potentially confounding factor for the association of depression 
symptoms with cardiac function. In model 2, we added potential socioeconomic confounders 
(i.e. education and marital status), and in model 3 established cardiovascular risk factors such 
as blood pressure, BMI, smoking and physical activity index were included. We investigated 
the potential effect modification by sex and age (dichotomized at age 50). Previous research 
have found a consistent sex difference across normal values of LV function (9, 16-18), and 
wee found signs of effect modification of gender with global strain (p=0.019) thus we 
stratified all our analysis by sex.  
We tested our models for violations of linear assumptions, including variance and 
normally distributed residuals, and the linear fit was tested with and without polynomials. We 
found no serious violations for using the linear line approach. All statistical analyses were 
performed in Stata IC/12.1 for Windows (© Stata Corp LP). 
 
Results 
Table 1 displays the characteristics of the study participants at baseline. Using the cut off 
which is recommended in order to ensure depression and anxiety symptom specificity, i.e a 
score 11 on the HADS-D and HADS-A, respectively, only 17 (1.6%) had depression and 30 
(2.9%) had anxiety. Thus, in this sub population of HUNT, which is a random selection free 
from known CVD, diabetes and hypertension, the prevalence of anxiety and depression 
“caseness” is lower than in the total HUNT population (1, 2).  
We found a negative correlation between the additive HADS-Depression scores from 
HUNT2 and HUNT3 with e´ (r -0.1628, p<0.001). Correlations between all 
echocardiographic measures and present depression scores and all anxiety scores were weak 
(r -0.05–0.04, all p values >0.09).  
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Table 2 shows that the point estimates for e´ were 2.53.2% lower per 5 units increase 
in HADS-Depression and HADS-Anxiety scores. For the additive HADS-D scores from 
HUNT 2 and 3, e´ was approximately 5% lower for women and men per 5 units of increase in 
HADS-D score. In contrast, additive anxiety symptoms had little impact on e´. The results 
from analyses after adjustment for socioeconomic status (Model 2) were similar to those in 
Model 1 (data not shown). Multivariable adjustment for age, education, marital status, systolic 
blood pressure, BMI, smoking, physical activity index and heart rate during echocardiography 
(Model 3) did not change the estimates substantially.  
Table 3 shows that the additive depression symptoms from HUNT2 and HUNT3, but 
not additive anxiety symptoms, have a marginal negative influence on global strain in women, 
but not in men. The percentage differences of S´, global strain rate and MAPSE with 
symptoms of depression and anxiety are provided in Supplementary Table I and II, 
respectively. Both depression symptoms and anxiety symptoms are associated with marginal 
lower effect estimates for S´ and MAPSE. However, for the measures shown in S-Table I and 
II, the statistical evidence is weak and not of clinical importance.  
 
Discussion 
In the present study of healthy individuals, additive depression symptoms from two reports, 
ten years apart, indicated lower LV function at follow-up. The negative influence was most 
pronounced in e´, as well as in strain in women. Symptoms of anxiety and present depression 
symptoms were less associated with cardiac function. As the study population consisted of 
healthy individuals the effect is unlikely to be caused by reverse causality or existing disease.  
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Comparisons with previous studies 
Strain and e’ are among the most sensitive echocardiographic indices with respect to detect 
subtle LV dysfunction, and are linked to different CVD risk factors and manifest CVD even 
though other indices of LV systolic and diastolic function have been less influenced (9, 22, 
23). To our knowledge only one echocardiography study using novel TD parameters has been 
published on the associations of LV diastolic function and depression symptoms (12). Unlike 
our study, the Korean study also included participants with cardiovascular risk factors, like 
hypertension, diabetes, metabolic syndrome and patients on antihypertensive medication (12). 
Such medical comorbidity can be important confounders in the observed association between 
depression symptoms and LV dysfunction (24). Further, subclinical cardiac disease or the 
presence of cardiovascular risk factors may trigger inflammatory activity or neurohormonal 
actions that mimic both the depressive symptoms (13, 15, 25) and cause the process of early 
LV remodeling (26). The association observed between depression symptoms and LV 
function in the Korean study could therefore reflect reverse causation. Thus, our study is the 
first to confirm that two reports of depression symptoms are associated with reduced LV 
function on a sub-clinical level. This finding supports our previous findings in the HUNT 
cohort of long lasting depression symptoms as a risk factor for myocardial infarctions and 
heart failure (1, 2).  
Even though depression symptoms often are episodic, most studies only use one-off 
measures of depression. Limited previous evidence suggests that recurrent depression 
symptoms are associated with higher risk of cardiac disease than a single episode (2, 14, 27, 
28). In the present study, the additive depression symptoms levels, measured twice in a ten 
years perspective, were correlated with LV subclinical dysfunction, but present depression 
symptoms and anxiety symptoms was not. Chronic stress, like long-lasting depression and 
anxiety symptoms, is previously found to be associated with neurohormonal and cytokine 
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release (29), and furthermore to modify the response to new stress events, i.e. creating a 
pattern of dysfunctional hormonal dynamics. Anhedonia, which is a core depressive feature 
measured by the HADS-Depression questionnaire, is previously described to produce such a 
chronic stress (30). It might be hypothesized that HADS anxiety questionnaire, which mirrors 
worries and tension, is less sensitive to neurohormonal stress and cytokine release than 
symptoms of anhedonia.  
The influence of current and additive anxiety symptoms levels on all 
echocardiographic indices of LV function was less pronounced than for depression symptoms. 
Depression symptoms have most often been associated with a stronger risk for various CVD 
diseases, like AMI and HF, than anxiety symptoms (1-3, 31). Anxiety and depression 
symptoms are associated with different behavioral patterns, where individuals with anxiety 
more often seek and cohere with medical and lifestyle advice (32, 33). Furthermore, 
compared to anxiety symptoms depression symptoms are more strongly linked to an 
unfavorable lifestyle (32) which may trigger pro-inflammatory cytokines (34) which may 
increase the risk for both depression symptoms and early cardiac remodeling that can lead to 
cardiac diseases (26), like heart failure (29, 35, 36). However, the association we observed 
between additive depression levels and e´ was not fully explained by unfavorable life-style. 
Thus, long lasting high reports on depression symptoms should be taken into account when 
discussing subclinical LV dysfunction. 
Strengths and Limitations  
This study has apparent strengths, like inclusion persons free from CVD, diabetes and 
hypertension, in addition to extensive adjustment for potential confounders, which make 
medical comorbidity and reverse causality less likely to explain the observed association. 
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The study also has some important limitations. The participants were healthy both 
with respect to anxiety and depression, and the results may not necessarily be generalizable to 
other populations (46). Future studies should include more patients with higher burden of 
anxiety and depression symptoms in order to evaluate the influence on LV function in such a 
population.  
Perspectives 
Detection of subclinical cardiac dysfunction related to long-lasting anhedonic depression 
symptoms is important from a pathophysiological and clinical point of view as it contributes 
to the understanding of the vulnerability of depressed patients to CVD and, thus, may lead to 
an earlier identification and an improved prevention of CVD.  
Further, a previous study from the echo population in HUNT3 allows us to compare 
the LV reduction associated with depression symptoms to traditional risk factors for CVD (9). 
A 5 unit higher additive HADS-Depression score from HUNT2 and HUNT3 gives similar 
detrimental effect of the cardiac function as 16 mm Hg and 13 mm Hg higher blood pressure 
in women and men, respectively. The corresponding values for age and non HDL cholesterol 
were 3.4 and 3.3 years and 2.8 and 1.1 mmol/L in women and men, respectively (9). Thus, 
compared to the associations of the well-known CVD risk factors on LV function, the effect 
size of repeated high levels of depression symptoms is not negligible.  
It may be argued that diagnosing asymptomatic disease is only useful if it can lead to 
clinical action that slows or stops progression of disease (39). In light of our findings that 
recurrent depression symptoms is associated with lower cardiac function, it is interesting that 
both the SADHART and CREATE trial found that persons with previous history of 
depression symptoms were especially responsive to medical treatment (40, 41). Those who 
did not respond to cognitive behavioral treatment in the ENRICHED trial could receive 
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antidepressant drugs on a non-randomized basis, and those who did had a 42% lower 
incidence of death or recurrent MI (40). It is therefore plausible that depression symptoms 
represent a modifiable risk factor for CVD. In clinical practice anxiety and depression co-
exists and it is advised to consider both conditions when planning treatment strategies (41). 
Furthermore, action directed to depression symptoms is often improving quality of life, which 
may be a standalone important target (41).  
 
Conclusion 
Repeated high levels of depression symptoms indicated lower LV function at follow-up 
among the healthy participant. The negative influence was most pronounced for diastolic 
function measured by early diastolic mitral annular velocity. Thus, long lasting depression 
symptoms should be taken into account when discussing subclinical LV dysfunction. 
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Table 1 Characteristics of the Study Population at Baseline 
Variable N Women Men 
  N (%) N (%) 
Sex (n) 1,034 544 (52.6) 490 (47.4) 
Smoking 1,018   
Never  239 (44.6) 252 (52.2) 
Former   163 (30.4) 124 (25.7) 
Current  134 (25.0) 106 (21.9) 
Marital Status 1,031   
Never Married  127 (23.5) 101 (20.7) 
Married  327 (60.3) 321 (65.6) 
Separated/ Divorced/Widowed  88 (16.2) 67 (13.7) 
Education 1,025   
9 years  83 (15.4) 54 (11.1) 
10-12 years  273 (50.7) 265 (54.4) 
>12 years  182 (33.8) 168 (34.5) 
  Mean (SD) Mean (SD) 
Age (years) 1,034 50.4 (14.1)  50.2 (13.4) 
Body Mass index (kg/ m2) 1,031 26.4 (4.0) 26.4 (3.8) 
PAI index 906 0.7 (0.8) 0.7 (0.8) 
Systolic blood pressure (mmHg) 1,024 127.3 (17.1) 135.0 (14.0) 
Diastolic blood pressure (mm Hg) 1,024 71.3 (11.6) 78.1 (11.2) 
Resting heart rate (bpm) 1,026 70.7 (11.2) 66.2 (11.1) 
Total serum cholesterol (mmol/L) 1,028 5.6 (1.0) 5.6 (1.0)  
HADS-Depression (0-21) 1,034 2.9 (2.8) 2.6 (2.5) 
HADS-Anxiety (0-21) 1,034 3.7 (3.0) 3.5 (2.8) 
Ejection Fraction (EF) 1,011 64.7 (10.1) 65.1 (9.6) 
Mitral Annular Plane Systolic 
Excursion (MAPSE) (cm) 
1,034 1.6 (0.3) 1.6 (0.2) 
Global strain (%) 1,034 -17.4 (2.3) -15.9 (2.2) 
Global strain rate (s-1) 1,018 -1.0 (-0.1) -1.0 (-0.1) 
Systolic annular velocity (S´) (cm/s) 1,023 8.2 (1.2) 8.6 (1.4) 
Diastolic annular velocity (e´) (cm/s) 1,023 11.9 (3.2) 10.7 (3.1) 
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Figure 1: Flow Chart of Study Recruitment 
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valvular pathology disclosed at echocardiography 
were excluded 
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